###begin article-title 0
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License () which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 768 771 768 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
Deoxyuridine triphosphate nucleotidohydrolase (dUTPase) catalyzes the hydrolysis of dUTP to dUMP and PPi. Although dUTP is a normal intermediate in DNA synthesis, its accumulation and misincorporation into DNA is lethal. Importantly, uracil misincorporation is a mechanism of cytotoxicity induced by fluoropyrimidine chemotherapeutic agents including 5-fluorouracil (5-FU) and elevated expression of dUTPase is negatively correlated with clinical response to 5-FU-therapy. In this study we performed the first functional characterization of the dUTPase promoter and demonstrate a role for E2F-1 and Sp1 in driving dUTPase expression. We establish a direct role for both mutant and wild-type forms of p53 in modulating dUTPase promoter activity. Treatment of HCT116 p53+/+ cells with the DNA-damaging agent oxaliplatin induced a p53-dependent transcriptional downregulation of dUTPase not observed in the isogenic null cell line. Oxaliplatin treatment induced enrichment of p53 at the dUTPase promoter with a concomitant reduction in Sp1. The suppression of dUTPase by oxaliplatin promoted increased levels of dUTP that was enhanced by subsequent addition of fluoropyrimidines. The novel observation that oxaliplatin downregulates dUTPase expression may provide a mechanistic basis contributing to the synergy observed between 5-FU and oxaliplatin in the clinic. Furthermore, these studies provide the first evidence of a direct transcriptional link between the essential enzyme dUTPase and the tumor suppressor p53.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 465 466 465 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 825 826 825 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1072 1073 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1196 1204 1196 1204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1209 1216 1209 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1473 1474 1473 1474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1579 1580 1579 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1661 1662 1661 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1839 1840 1839 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 2039 2041 2039 2041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 2231 2233 2231 2233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1354 1359 <span type="species:ncbi:4932">yeast</span>
###xml 2029 2037 <span type="species:ncbi:9606">patients</span>
Deoxyuridine triphosphate nucleotidohydrolase (dUTPase) is the sole enzyme responsible for the hydrolysis of dUTP to dUMP and pyrophosphate simultaneously providing substrate for thymidylate synthase (TS) and eliminating dUTP from the DNA biosynthetic pathway. Although dUTP is a normal intermediate in DNA synthesis, its extensive accumulation and misincorporation into DNA is lethal in both prokaryotic and eukaryotic organisms as evidenced from knockout models (1,2). Importantly, uracil misincorporation also represents a major mechanism of cytotoxicity induced by the TS-inhibitor class of chemotherapeutic agents including the fluoropyrimidines 5-fluorouracil (5-FU), fluorodeoxyuridine (FUdR) and capecitabine which are broadly used in the treatment of cancers of the gastrointestinal tract, breast and head and neck (3). Inhibition of TS induces a metabolic blockade, depleting thymidylate pools and in some instances promoting the accumulation of intracellular dUTP pools and subsequent misincorporation of uracil into DNA resulting in DNA damage and cell death (4,5). Expression of dUTPase is reported to be an important mediator of resistance to therapeutic agents that target TS both in vitro and in vivo. We previously demonstrated that diminished dUTPase expression greatly enhanced dUTP pool expansion following TS-inhibition, sensitizing yeast cells to the effects of uracil misincorporation while cells overexpressing dUTPase were significantly protected (6). In colon cancer cells, depletion of dUTPase by siRNA resulted in dUTP accumulation and growth arrest (7). Overexpression of dUTPase was also demonstrated to confer resistance to FUdR (8), while we previously reported that depletion of dUTPase by siRNA sensitized both breast and colon cell lines to FUdR through misincorporation of dUTP and enhanced DNA damage (9). Moreover, we also reported the results of a retrospective clinical study negatively correlating elevated nuclear expression of dUTPase with response to 5-FU-therapy in colorectal cancer patients (10). These studies bolster the concept that dUTPase represents an attractive drug target and we recently reported the identification of novel small molecules with dUTPase inhibitory activity (11).
###end p 4
###begin p 5
###xml 185 190 185 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12 B13 B14">12&#8211;14</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 665 667 665 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 913 915 913 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1184 1186 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1187 1189 1187 1189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1190 1192 1190 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1566 1569 1566 1569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUT</italic>
###xml 1694 1696 1690 1692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1809 1811 1805 1807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 116 121 <span type="species:ncbi:9606">human</span>
While detailed analyses of dUTPase structure and catalytic activity have been described, the mechanisms that govern human dUTPase gene regulation and expression remain largely unknown (12-14). Previous studies have reported that expression of the nuclear isoform of dUTPase (DUT-N) is primarily cell cycle and proliferation-dependent, whereas the mitochondrial isoform (DUT-M) is constitutively expressed (15). Immunohistochemical staining of normal tissues demonstrated that high DUT-N expression is exclusively observed in replicating cell types whereas cytoplasmic expression is observed in mitochondria-rich tissues (10). However, both colon cancer cell lines (16) and tumor specimens demonstrate dramatic variation, both in magnitude of dUTPase expression and intracellular localization. Furthermore, the correlation between replication status and DUT-N expression was not observed in colon adenocarcinomas (17). Importantly, dysregulation of dUTPase expression is observed in tumor types which are frequently treated with agents that target TS, therefore elucidating the molecular basis driving dUTPase expression is important from both a basic science and clinical standpoint (10,16,17). Functional analyses of various S-phase-specific genes including TS and thymidine kinase (TK) identified several transcriptional elements that are commonly present in their promoter regions including E2F and Sp1 consensus sites. These genes are also characterized by a lack of TATA or CAAT box initiation sites, but are rich in GC boxes. Promoter sequence analysis of the DUT gene reveals putative regulatory motifs including potential binding sites for NF-kappaB, E2F and Sp1 transcription factors (15). Recently, a genome-wide ChIP-on-chip identified dUTPase in a subset of 127 genes bound by E2F family members (18). Despite the presence of these putative S-phase-specific binding sites in the DUT-N promoter region, functional analysis of this gene has not been previously reported.
###end p 5
###begin p 6
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 82 84 82 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 328 337 328 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cip1/waf1</sup>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
Several studies have also reported downregulation of dUTPase during apoptosis (19,20) and that dUTPase expression may be modulated by the tumor suppressor gene p53 (21,22). In response to stress stimuli such as DNA damage, p53 can initiate cell cycle arrest through transcriptional induction of cell cycle inhibitors such as p21cip1/waf1, mediate DNA repair or induce apoptotic cell death. These mechanisms are designed to prevent proliferation of cells containing damaged DNA and reduce the likelihood of tumor formation. Interestingly, mutations in p53 are one of the most common genetic aberrations detected in malignant disease with >50% of colon tumors exhibiting mutation (23).
###end p 6
###begin p 7
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 794 796 794 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 676 681 <span type="species:ncbi:10090">mouse</span>
###xml 734 739 <span type="species:ncbi:9606">human</span>
In prostate cancer cells, dUTPase was one of many genes identified by microarray analysis as significantly repressed following introduction of wild-type p53 (22). In MCF-7 (p53 wild-type) breast cancer cells, microarray analysis also identified dUTPase mRNA within an extensive panel of genes repressed following 5-FU treatment (21). However, the precise mechanism of the downregulation of dUTPase has not been determined and it is unknown as to whether this phenomenon is the result of indirect downstream events induced by p53 itself or its transactivation and repressive gene targets. Furthermore, dUTPase was one of a number of genes identified as upregulated in p53-null mouse embryonic fibroblasts following introduction of the human tumor-derived p53 R175H by subtraction hybridization (24).
###end p 7
###begin p 8
###xml 1246 1253 1246 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
As dUTPase is an essential enzyme in maintaining genomic stability, and demonstrates both aberrant intratumoral expression and an association with resistance to 5-FU, we sought to perform the first functional characterization of the promoter and elucidate the mechanisms involved in regulating dUTPase expression. In addition, p53 mutations are widely observed in many cancers and as the fluoropyrimidines remain the mainstay chemotherapeutics in gastrointestinal cancer treatment, characterizing a role for p53 in regulating dUTPase gene expression in tumor cells may be of major clinical significance and may lead to more targeted therapeutic options. In this study, we demonstrate direct roles for Sp1 and E2F-1 in driving basal DUT-N expression and report a direct role for wild type and mutant p53 in repressing and inducing dUTPase promoter activity respectively. Furthermore, we demonstrate the ability of oxaliplatin, an important chemotherapeutic agent primarily used in combination with 5-FU in the treatment of colorectal cancer, to acutely suppress the dUTPase promoter, mRNA and protein expression and enzymatic activity in a p53-dependent manner. We also present evidence that p53 is associated with the endogenous dUTPase promoter in vivo, and propose that interference with transcription machinery at the dUTPase promoter by wild-type p53 represents a plausible mechanism for this transcriptional repression. Finally, suppression of dUTPase by oxaliplatin resulted in the expansion of intracellular dUTP pools and subsequently enhanced the downstream effects of TS-inhibition. This interaction may contribute to the clinical synergy observed between 5-FU and oxaliplatin in the treatment of colorectal cancer.
###end p 8
###begin title 9
MATERIALS AND METHODS
###end title 9
###begin title 10
Compounds and reagents
###end title 10
###begin p 11
5-FU, fluorodeoxyuridine (FUdR), paclitaxel, doxycycline (DOX), G418 and mithramycin A were purchased from Sigma (St Louis, MO). Oxaliplatin was obtained with permission from Sanofi Synthelabo (Bridgewater, NJ).
###end p 11
###begin title 12
Cell culture
###end title 12
###begin p 13
###xml 44 47 44 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 59 62 59 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 77 80 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 284 294 284 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 689 690 683 684 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 284 294 <span type="species:ncbi:7227">Drosophila</span>
###xml 473 479 <span type="species:ncbi:9913">bovine</span>
The human colon cancer cell lines HCT116 p53+/+, HCT116 p53-/- and HCT116 p21-/- cell lines, generated via homologous recombination, were generous gifts from the laboratory of Dr Bert Vogelstein at Johns Hopkins University (Baltimore, MD). HCT116 cell lines were grown in McCoy's 5A. Drosophila SL2 cells (Invitrogen, Carlsbad, CA) were grown in Schneider's Insect media (Sigma) supplemented with 10% heat-inactivated serum. All other media was supplemented with 10% fetal bovine serum (Lonza, East Rutherford, NJ) with penicillin/streptomycin, and sodium pyruvate (Invitrogen). Cells were maintained in a humidified Forma incubator (Thermoscientific, Waltham, MA) at 37degreesC with 5% CO2. All cell lines were routinely screened for the presence of mycoplasma using the MycoALERT assay (Lonza, Rockland, ME).
###end p 13
###begin title 14
Generation of overexpression constructs
###end title 14
###begin p 15
###xml 369 372 369 372 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 879 886 879 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 1081 1083 1077 1079 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1096 1098 1092 1094 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1137 1140 1133 1136 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 1216 1217 1212 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 879 886 <span type="species:ncbi:562">E. coli</span>
The pPac0 and pPac-Sp1, pN3 empty vector (EV) and pN3-Sp1 were a kind gift from Dr Guntram Suske from the Institut Fur Molekularbiologie und Tumorforschung (Marburg, Germany). Chemically synthesized primers incorporating restriction endonuclease sites were used to generate PCR fragments corresponding to the DUT-N and p53 wild-type coding sequences from the HCT116 p53+/+ cell line. Cloning was performed as previously described (25). cDNA corresponding to the p53 R175H mutant was generated using site-directed mutagenesis of p53 wild type: 5'-CGT TGT GAG GCA CTG CCC CCA CC-3'. Briefly, The cDNA fragments were gel purified using the QIAquick gel purification kit (QIAGEN, Valencia, CA) and ligated into the pre-digested pTRE-Tight vector (BD Clontech, Mountainview, CA) for DUT-N, and pCI-Neo for the p53 cDNA using standard methods. Recombinant DNA was transformed into the E. coli host strain DH5alpha, DNA isolated and analyzed by restriction digest and sequenced for orientation and integrity of the gene insert. Functionality of the nuclear dUTPase (pTre-Tight:DUT-N), p53WT (pCI-Neo:p53WT) and the p53 R175H mutant (pCI-Neo:p53MUT) constructs were confirmed by transient transfection and Western blotting (9).
###end p 15
###begin title 16
Generation of the HCT116 pTet-Off cell line
###end title 16
###begin p 17
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 54 55 54 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 112 114 112 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
HCT116 p53+/+ cells were seeded at a density of 1 x 106 on a 10 cm plate for 24 h, transfected using ExpressfectTM (Denville Scientific, Metuchen, NJ) with 2 microg of the pTet-Off plasmid (BD Clontech). Six hours post-transfection, complexes were removed, cells were washed once with PBS and fresh medium was added. After 24 h, cells were trypsinised into six 10 cm plates for 24 h before media containing G418 (800 microg/ml) was added. After selection for approximately 14 days, colonies were isolated and expanded. Potential pTet-Off cells were tested for tetracycline-repressible expression by transient transfection with the pTre-Tight:Luc (BD Clontech) in media containing 10% tet-approved FBS (BD Clontech) in the presence and absence of DOX (500 ng/ml).
###end p 17
###begin title 18
Overexpression of dUTPase
###end title 18
###begin p 19
HCT116 pTet-Off cells were seeded on 6 cm plates and 3 h after plating the cells were washed with PBS and growth media containing 10% tet-approved FBS (BD Clontech) added. Cells were transfected after 24 h with 2 microg pTre-Tight:DUT-N for 6 h, washed in PBS and fresh media added. Twenty-four hours post-transfection, media containing the appropriate cytotoxic agent was added. Cells were harvested for protein after 48 h incubation and inducible expression of dUTPase confirmed using Western blotting and enzyme activity assay.
###end p 19
###begin title 20
dUTPase promoter constructs
###end title 20
###begin p 21
###xml 225 227 225 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
The 1.2 kb region of the dUTPase promoter upstream of the transcriptional start site was previously reported to encompass all putative transcription factor-binding sites with high correlation to reported consensus sequences (15). This region was amplified by PCR using chemically synthesized primers (5'- GGT TCC CAC TGC GTT TCT G; 3'-CTC TCC TCT TCC CCC GGT G) and the generated 1.231 kb fragment cloned into the pGL3-Basic immediately upstream of the firefly luciferase gene and was termed the 'full length'. Promoter truncations were performed using the following primers followed by re-ligation: pGL3:608 (5'-CGA AGC CGC GGT ACT CTC C-3'), pGL3:162 (5'-GAA GGG CTT CAA ACC CAA AAT-3'), pGL3:65 (5'-GAA ATT TCG GTT TTG GCG C-3').
###end p 21
###begin title 22
Site-directed mutagenesis
###end title 22
###begin p 23
###xml 125 133 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 445 447 439 441 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</underline>
###xml 441 448 435 442 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGC <underline>TT</underline>G</bold>
###xml 495 497 489 491 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</underline>
###xml 493 501 487 495 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G <underline>TT</underline>C GG</bold>
###xml 529 531 523 525 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</underline>
###xml 527 535 521 529 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G <underline>TT</underline>C GG</bold>
###xml 778 780 766 768 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AT</underline>
###xml 769 782 757 770 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GTT TTG G<underline>AT</underline> C</bold>
Targeted site-specific mutagenesis of Sp1- and E2F-binding sites in the dUTPase promoter were performed using the GeneEditor in vitro Site-Directed Mutagenesis System (Promega, Madison, WI) according to manufacturer's instructions. Briefly, the triple Sp1 mutant (pGL3:Sp1Delta) was generated by double base mutation from GG-->TT (underlined) within the Sp1 site indicated in bold, using the following chemically synthesized primers, 5'-GCT GGC TTG AAA TTT CGG TTT TG-3', 5'-CTC GTC CCG GGG AGG TTC GGT GGG TGG GGC GG-3', 5'-TGG TTC GGG GCT GGC TTG AAA TTT CGG TTT TG-3' in three consecutive rounds of mutagenesis. The E2F mutant (pGL3:E2FDelta) was generated by double base mutation from CG-->AT (underlined) within the E2F site indicated in bold using 5'-GAA ATT TCG GTT TTG GAT CTC TCC CTG CGG C-3' (). The integrity of each site-specific mutant was confirmed by direct DNA sequencing.
###end p 23
###begin title 24
Antibodies and western blotting
###end title 24
###begin p 25
###xml 101 102 101 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 440 442 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
At specified time points, cells were collected and analyzed by western blot as described previously (9). Blots were probed overnight at 4degreesC with the following antibodies from Santa Cruz Biotechnology (Santa Cruz, CA) at specified dilutions: anti-p53 (1 : 2000), anti-p21 (1 : 1000), anti-Sp1 (1 : 2000), anti-E2F-1 (1 : 1000) and anti-beta-actin (1 : 4000). Affinity purified anti-dUTPase was used at 1 : 500 as previously described (26).
###end p 25
###begin title 26
Growth inhibition assay
###end title 26
###begin p 27
###xml 43 44 43 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
Cells were seeded in 96-well plates at 3x103 and exposed to 5-FU, FUdR or oxaliplatin, alone and in combination for 72 h. Growth inhibition was measured as previously described (9) using CellTiter 96(R) AQueous One Solution (Promega). Absorbance was measured using a SpectraMax 190 microplate reader (Molecular Devices, Sunnyvale, CA) at 490 nm. Fraction affected (FA) was calculated from the percent growth inhibition using the following equation: (100 - percent growth inhibition)/100. Statistical significance was determined using a two-way ANOVA (Graphpad, San Diego, CA).
###end p 27
###begin title 28
dUTP accumulation assay
###end title 28
###begin p 29
###xml 10 13 10 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 381 383 381 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 879 880 879 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
HCT116 p53+/+ cells were treated with specified concentrations of 5-FU, FUdR, paclitaxel and oxaliplatin or combinations for indicated times, harvested and resuspended in PBS. Cells were analyzed for nucleotide pool content using the assay developed by Sherman and Fyfe (27) modified to detect levels of TTP and dUTP by pre-incubating cellular extracts with recombinant dUTPase (9,28). The amount of radioactive incorporation, measured in the presence of dUTPase represented the TTP pool only, while untreated extracts represented both the dUTP and TTP pools. The amount of dUTP accumulation was determined by subtracting the results of extracts treated with dUTPase from the untreated extracts and presented as percentage accumulation in histogram format. The differences between treatment groups were analyzed for statistical significance using a two-tailed unpaired Student's t-test (Graphpad).
###end p 29
###begin title 30
dUTPase activity assay
###end title 30
###begin p 31
###xml 172 173 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
Twenty-five micrograms of total protein was normalized to a 20 microl volume with PBS/protease inhibitor. Relative dUTPase activity was determined as previously described (9), and expressed as a percentage relative to the appropriate untreated time-matched control.
###end p 31
###begin title 32
RNA isolation, cDNA synthesis and quantitative real-time RT-PCR (qPCR)
###end title 32
###begin p 33
###xml 300 302 300 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 375 382 375 382 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">dUTPase</bold>
###xml 375 382 375 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><bold>dUTPase</bold></italic>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 491 493 491 493 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TS</bold>
###xml 491 493 491 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><bold>TS</bold></italic>
###xml 603 606 601 604 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">18S</bold>
###xml 603 606 601 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><bold>18S</bold></italic>
###xml 712 717 708 713 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</bold>
###xml 712 717 708 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><bold>GAPDH</bold></italic>
###xml 781 783 777 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 869 870 863 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 870 871 864 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 986 987 978 979 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 987 988 979 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1199 1210 1191 1194 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;&#916;&#916;</sup>
###xml 1210 1211 1194 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1211 1212 1195 1196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1221 1223 1205 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1472 1473 1456 1457 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
RNA was isolated using Trizol as per manufacturers method (Invitrogen) and subjected to lithium chloride precipitation. cDNA was reverse transcribed using 200 ng total RNA following M-MLV-RT protocol (Invitrogen). qPCR was conducted using the ABI 7500 (Applied Biosystems, Foster City, CA) and PlexorTM multiplex (Promega). Probe sets used for qPCR analysis were as follows: dUTPase 5'-FAMTM-iso-dC-GGG AGA TCA TAT GAG TTA AAT ACA GGC TTT TTT T-3', 5'-GGT GAC CTG ATG TAA ACA GTG TCT TC-3'; TS 5'-Cal Fluor(R) Orange 560-iso-dC-CCA TGT CTC CCG ATC TCT GGT-3', 5'-TGG AAT CCA AGA GAT CTT CCT CTG ATG-3'; 18S 5'-Cal Fluor(R) Red 610-iso-dC-GCA TCG TTT ATG GTC GGA ACT ACG-3', 5'-TTG TTG GTT TTC GGA ACT GAG GC-3'. GAPDH is a pre-validated house-keeping gene purchased with the PlexorTM multiplex system and was detected as Cal Fluor(R) Red 610. Standard curves with >0.95R2 and PCR-efficiency at 100 +/- 2% were confirmed for each primer set within the multiplex. Threshold cycle values (CT) were determined from three independently isolated RNA samples and performed in triplicate. dUTPase and TS mRNA expression levels were determined by normalizing against both 18S and GAPDH expression using the 2-DeltaDeltaCT method (29) and calibrated against appropriate time-matched controls. mRNA expression is presented in a histogram as a percentage of the appropriate untreated time-matched control. Statistical significance was determined using a two-tailed unpaired Student's t-test (Graphpad).
###end p 33
###begin title 34
Transient transfection and luciferase promoter assay
###end title 34
###begin p 35
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 182 184 174 176 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 242 244 234 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 410 412 402 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 425 428 417 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 618 628 610 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 1739 1746 1719 1726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 2201 2202 2181 2182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 0 10 <span type="species:ncbi:7227">Drosophila</span>
###xml 618 628 <span type="species:ncbi:7227">Drosophila</span>
Drosophila SL-2 cells and HCT116 isogenic lines were seeded in a 24-well plate. Transient transfections were performed using plasmid DNA normalized to 0.25 microg/microl using FugeneTM (Roche, Basel, Switzerland) for SL2 cells and ExpressfectTM (Denville) for HCT116 cells, according to manufacturer's instructions. The dUTPase pGL3 promoter constructs were transfected alone or co-transfected with pCI-Neo:p53WT, pCI-Neo:p53MUT and the corresponding pCI-Neo EV. Additional experiments were performed by co-transfecting the appropriate dUTPase promoter construct with the mammalian pN3-Sp1 or pN3 EV constructs or the Drosophila pPac-Sp1 and pPac0 constructs. All wells were transfected with 0.2 microg of the appropriate construct with co-transfections totaling 0.4 microg DNA. The pRL-TK plasmid was included in all transfections at a ratio of 1 : 10 (control : reporter) to account for transfection efficiency. The pGL3-Basic EV was also tested with all expression constructs and cytotoxic agents to discount non-specific effects. Six hours post-transfection, cells were washed with PBS and incubated in either fresh media or media containing a cytotoxic agent at the appropriate concentration. After an additional 30 h, cells were washed once with PBS, lysed and quantified as per western blotting methodology to account for variation in cell number. Twenty-five micrograms of total protein was normalized to 20 microl and analyzed using the dual-luciferase reporter assay (Promega) in a TD 20/20 luminometer (Turner Biosystems, Sunnyvale, CA). Three independent promoter experiments were performed, each transfection in triplicate and the mean of two firefly luminescence readings recorded, subsequently the reaction was quenched and Renilla luciferase measured. Co-transfection experiments investigating the effects of Sp1 overexpression were subject only to correction for protein concentration due to non-specific effects of Sp1 on the pRL-TK vector. Histograms are presented as normalized relative luciferase, or fold-change compared to control as appropriate. The differences between comparative transfections were analyzed for statistical significance using a two-tailed unpaired Student's t-test (Graphpad).
###end p 35
###begin title 36
RNAi
###end title 36
###begin p 37
###xml 197 199 197 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
Two million cells were plated for 24 h and subsequently transfected using Lipofectamine RNAiMax (Invitrogen) alone (Mock) or with 100 nM scrambled control siRNA (Scr) or 100 nM of validated StealthTM DuoPak siRNA targeting Sp1 (Invitrogen). For western blotting, cells were harvested after 72 h for analysis of dUTPase, Sp1 and beta-actin protein expression. For dUTPase promoter activity, siRNA-transfected cells were trypsinised after 24 h and re-plated in 24-well plates and allowed to adhere for 24 h before transfection with the pGL3:FL dUTPase promoter for 30 h.
###end p 37
###begin title 38
Chromatin immunoprecipitation (ChIP)
###end title 38
###begin p 39
###xml 1194 1202 1156 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1230 1231 1192 1193 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1231 1232 1193 1194 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1411 1412 1369 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1412 1413 1370 1371 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1416 1417 1374 1375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1417 1418 1375 1376 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1432 1433 1390 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 1433 1434 1391 1392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 1447 1456 1405 1414 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 1503 1504 1461 1462 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1570 1573 1528 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUT</italic>
###xml 1699 1700 1657 1658 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1818 1821 1772 1775 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1847 1848 1801 1802 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2047 2048 1993 1994 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2166 2169 2108 2111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2347 2348 2287 2288 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2359 2360 2299 2300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2372 2373 2312 2313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1456 2403 1414 2343 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="40">Systematic analysis of dUTPase gene promoter. (<bold>A</bold>) Schematic diagram illustrating the basic layout of the proximal <italic>DUT</italic> gene promoter and promoter truncations cloned into the pGL3-Basic promoterless vector encoding the firefly luciferase gene. (<bold>B</bold>) Relative luciferase activity of dUTPase promoter constructs (0.2 &#181;g) transiently transfected into the HCT116 p53<sup>+/+</sup> colon cancer cell line. (<bold>C</bold>) Schematic diagram illustrating the site-specific triple Sp1 (pGL3:Sp1&#916;) and E2F mutant (pGL3:E2F&#916;) generated by site-directed mutagenesis as outlined in &#8216;Experimental Procedures&#8217; section. (<bold>D</bold>) Relative luciferase activity of dUTPase promoter constructs (0.2 &#181;g) transiently transfected into the HCT116 p53<sup>+/+</sup> colon cancer cell line. Transfections were performed as outlined in &#8216;Experimental Procedures&#8217;. Histogram bars represent mean &#177; SEM of three independent promoter experiments. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p>
###xml 1456 2403 1414 2343 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="40">Systematic analysis of dUTPase gene promoter. (<bold>A</bold>) Schematic diagram illustrating the basic layout of the proximal <italic>DUT</italic> gene promoter and promoter truncations cloned into the pGL3-Basic promoterless vector encoding the firefly luciferase gene. (<bold>B</bold>) Relative luciferase activity of dUTPase promoter constructs (0.2 &#181;g) transiently transfected into the HCT116 p53<sup>+/+</sup> colon cancer cell line. (<bold>C</bold>) Schematic diagram illustrating the site-specific triple Sp1 (pGL3:Sp1&#916;) and E2F mutant (pGL3:E2F&#916;) generated by site-directed mutagenesis as outlined in &#8216;Experimental Procedures&#8217; section. (<bold>D</bold>) Relative luciferase activity of dUTPase promoter constructs (0.2 &#181;g) transiently transfected into the HCT116 p53<sup>+/+</sup> colon cancer cell line. Transfections were performed as outlined in &#8216;Experimental Procedures&#8217;. Histogram bars represent mean &#177; SEM of three independent promoter experiments. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption>
###xml 2403 2403 2343 2343 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn910f1"/>
###xml 1447 2403 1405 2343 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="40">Systematic analysis of dUTPase gene promoter. (<bold>A</bold>) Schematic diagram illustrating the basic layout of the proximal <italic>DUT</italic> gene promoter and promoter truncations cloned into the pGL3-Basic promoterless vector encoding the firefly luciferase gene. (<bold>B</bold>) Relative luciferase activity of dUTPase promoter constructs (0.2 &#181;g) transiently transfected into the HCT116 p53<sup>+/+</sup> colon cancer cell line. (<bold>C</bold>) Schematic diagram illustrating the site-specific triple Sp1 (pGL3:Sp1&#916;) and E2F mutant (pGL3:E2F&#916;) generated by site-directed mutagenesis as outlined in &#8216;Experimental Procedures&#8217; section. (<bold>D</bold>) Relative luciferase activity of dUTPase promoter constructs (0.2 &#181;g) transiently transfected into the HCT116 p53<sup>+/+</sup> colon cancer cell line. Transfections were performed as outlined in &#8216;Experimental Procedures&#8217;. Histogram bars represent mean &#177; SEM of three independent promoter experiments. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption><graphic xlink:href="gkn910f1"/></fig>
###xml 706 712 <span type="species:ncbi:9986">rabbit</span>
Three million cells were plated for 24 h and treated with the appropriate cytotoxic agent for a further 12 h. ChIP was performed using the EZ-ChIP kit (Upstate/Millipore, Temecula, CA) according to the manufacturers' instructions. Briefly, DNA-protein cross-linking was achieved by addition of 1% formaldehyde to media. Cross-linked chromatin was sonicated on ice to approximately200 bp, verified by gel electrophoresis, purified and incubated with 5 microg of the appropriate ChIP-validated antibody: Sp1 5 microg; (Millipore), E2F-1 5 microg, p53 5 microg (Santa Cruz), by overnight rotation at 4degreesC, washed and cross-linking reversed. Parallel IPs using the kit-supplied anti-acetyl H3 (Ac-H3) and rabbit IgG as positive and negative controls respectively were performed. For qPCR, recovered IP chromatin and total input DNA were resuspended in 50 microl of TE buffer. qPCR was performed using Dynamo SYBR green (New England BioLabs, Beverly, MA), standard PCR protocol and PCR primers flanking the dUTPase promoter (-39 to -260) generating a 221 bp product encompassing the triple Sp1 sites and E2F site: Upper 5'-CAC CAG AAC TGT GGA CTC GT-3'. Lower 5'-CAG GGA GCG CGC CAA AAC CG-3' (Figure 1A). Threshold cycle values (CT) were determined in triplicate for each treatment from two independent IP samples, calibrated against input and compared to control IgG using the following equation:  where DeltaCT = CT(IP sample) - CT(DNA input). Figure 1.Systematic analysis of dUTPase gene promoter. (A) Schematic diagram illustrating the basic layout of the proximal DUT gene promoter and promoter truncations cloned into the pGL3-Basic promoterless vector encoding the firefly luciferase gene. (B) Relative luciferase activity of dUTPase promoter constructs (0.2 microg) transiently transfected into the HCT116 p53+/+ colon cancer cell line. (C) Schematic diagram illustrating the site-specific triple Sp1 (pGL3:Sp1Delta) and E2F mutant (pGL3:E2FDelta) generated by site-directed mutagenesis as outlined in 'Experimental Procedures' section. (D) Relative luciferase activity of dUTPase promoter constructs (0.2 microg) transiently transfected into the HCT116 p53+/+ colon cancer cell line. Transfections were performed as outlined in 'Experimental Procedures'. Histogram bars represent mean +/- SEM of three independent promoter experiments. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant.
###end p 39
###begin p 40
###xml 47 48 47 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 114 117 114 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUT</italic>
###xml 243 244 243 244 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 362 365 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 391 392 387 388 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 591 592 579 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 710 713 694 697 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 891 892 873 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 903 904 885 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 916 917 898 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Systematic analysis of dUTPase gene promoter. (A) Schematic diagram illustrating the basic layout of the proximal DUT gene promoter and promoter truncations cloned into the pGL3-Basic promoterless vector encoding the firefly luciferase gene. (B) Relative luciferase activity of dUTPase promoter constructs (0.2 microg) transiently transfected into the HCT116 p53+/+ colon cancer cell line. (C) Schematic diagram illustrating the site-specific triple Sp1 (pGL3:Sp1Delta) and E2F mutant (pGL3:E2FDelta) generated by site-directed mutagenesis as outlined in 'Experimental Procedures' section. (D) Relative luciferase activity of dUTPase promoter constructs (0.2 microg) transiently transfected into the HCT116 p53+/+ colon cancer cell line. Transfections were performed as outlined in 'Experimental Procedures'. Histogram bars represent mean +/- SEM of three independent promoter experiments. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant.
###end p 40
###begin p 41
###xml 320 321 320 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Changes in promoter enrichment for Ac-H3, Sp1, E2F and p53 following drug treatment are expressed as fold enrichment over control IgG or fold increase compared to untreated time-matched controls where appropriate with differences between ChIPs analyzed for statistical significance using a two-tailed unpaired Student's t-test (Graphpad). Semi-quantitative ChIP analysis was performed using the same primers, standard three-step PCR amplification with products visualized by gel electrophoresis. As a control, IP DNA was subjected to PCR using primers targeting the dUTPase ORF to verify amplification only in 'input' DNA.
###end p 41
###begin title 42
Electrophoretic mobility shift assay (EMSA)
###end title 42
###begin p 43
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 325 327 325 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
Electrophoretic mobility shift analyses were performed as described earlier with minor modification (30). Synthetic double-stranded oligonucleotides (Integrated DNA Technologies, Coralville, IA) corresponding to the -64 to -91 from the DUT-N transcriptional start site and encompassing the triple Sp1 site were labeled with [32P]ATP (Amersham Pharmacia Biotech) according to the Gel-Shift Assay Kit protocol (Promega). For each gel shift reaction, 10 000 cpm of labeled probe were incubated with approximately70 fmol of recombinant Sp1. Where indicated, unlabeled competitor oligonucleotides were incubated for 10 min at room temperature with Sp1 before the addition of labeled probe. Sequences of the oligonucleotides were as follows: DUT Sp1, 5'-GGG CGG TGG GTG GGG CGG GGC TGG CGG G-3'; DUT Sp1Delta, 5'-GTT CGG TGG GTG GTT CGG GGC TGG CTT G-3'.
###end p 43
###begin title 44
RESULTS
###end title 44
###begin title 45
Functional analysis of the dUTPase promoter
###end title 45
###begin p 46
###xml 443 445 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 601 603 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 668 675 664 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1347 1355 1343 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1410 1413 1406 1409 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1681 1689 1677 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 2204 2212 2196 2204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 358 363 <span type="species:ncbi:9606">human</span>
###xml 690 695 <span type="species:ncbi:9606">human</span>
Due to the critical role of dUTPase in maintaining genomic stability, the aberrant expression observed in neoplastic tissues and the reported role of dUTPase in resistance to chemotherapy, we sought to elucidate the transcriptional mechanisms driving dUTPase gene expression. We previously performed a computational sequence analysis of the 5' region of the human dUTPase gene and identified putative binding sites for NFkappa-B, Sp1 and E2F (15) (). The presence of Sp1- and E2F-binding sites is consistent with the hypothesis that the dUTPase promoter is regulated in a cell-cycle-dependent manner (31). However, to date there have been no studies investigating the in vivo regulation of human dUTPase at the promoter level. To address this, we first sought to determine the basal DNA regulatory elements of the dUTPase promoter that are required for expression. We utilized a luciferase-based system employing the pGL3-Basic promoterless vector and sub-cloned deletion mutant fragments targeting the putative E2F- and Sp1-binding sites reported to be critical for S-phase gene expression. We generated a series of four dUTPase promoter truncations ranging from the designated 'full length' (pGL3:FL) which incorporates the 1.231 kb proximal promoter upstream of the DUT-N transcriptional start site, to the extensive truncation mutant pGL3:65 (Figure 1A) and analyzed luciferase expression in the HCT116 p53+/+ colon cancer cell line model. Truncation of the pGL3:FL to the pGL3:608 resulted in an insignificant decrease of 1.22-fold in promoter activity, suggesting that the 5' region of the proximal dUTPase promoter may contain relatively minor positive regulatory elements (Figure 1B). A significant reduction in promoter activity of 2-fold was observed between the pGL3:608 and the pGL3:162 which differ by the consensus NFkappa-B-binding site. A 2.9-fold reduction was observed when the pGL3:162 was truncated to the pGL3:65 to exclude the triple Sp1 sites. The pGL3:65 that contains only the E2F site demonstrated a significant 7.2-fold reduction in luciferase activity compared to the pGL3:FL. Of note, the activity of pGL3:65 remained 3.4-fold higher than the pGL3-Basic promoterless vector (Figure 1B). These data suggest that consensus sequences for NFkappa-B, E2F and to a greater extent Sp1 may positively contribute to dUTPase promoter activity.
###end p 46
###begin title 47
Identification of transcription factors involved in dUTPase gene expression
###end title 47
###begin p 48
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DUT</italic>
###xml 591 599 583 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 703 706 687 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 952 960 936 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
Sp1 and E2F family members are known to be key regulators of S-phase gene promoters (32). Having identified the region of the DUT gene promoter containing the Sp1 and E2F transcription sites to be associated with positive regulation, we sought to determine the relative contributions of both Sp1 and E2F consensus sequences to dUTPase promoter activity. We utilized site-directed mutagenesis of the pGL3:FL to disrupt the triple Sp1 (pGL3:Sp1Delta) and E2F sites (pGL3:E2FDelta) by double nucleotide substitution within each respective site to generate mutant dUTPase luciferase constructs (Figure 1C and ). We transiently transfected the pGL3:FL, pGL3:Sp1Delta and the pGL3:E2FDelta into the HCT116 p53+/+ cells and analyzed their basal promoter activity. Mutation of the triple Sp1 sites decreased dUTPase promoter activity 1.7-fold while disruption of the E2F site resulted in a 2.6-fold reduction in promoter activity when compared to the pGL3:FL (Figure 1D). This data further establish and confirms the role of Sp1 and E2F sites as positive regulators of dUTPase promoter activity.
###end p 48
###begin title 49
The role of Sp1 in dUTPase gene expression
###end title 49
###begin p 50
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 429 439 429 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 963 971 963 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1143 1152 1143 1152 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 1197 1198 1197 1198 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1357 1367 1349 1359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 1380 1381 1372 1373 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1504 1507 1496 1499 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1721 1724 1702 1705 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1973 1974 1952 1953 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2030 2033 2009 2012 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2130 2132 2109 2111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 2386 2389 2358 2361 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2449 2451 2421 2423 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 2561 2562 2531 2532 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2608 2615 2578 2585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2893 2894 2863 2864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2906 2907 2876 2877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1152 2937 1152 2907 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="51">The role of Sp1 in dUTPase gene expression. (<bold>A</bold>) Relative luciferase activity of dUTPase full-length promoter (pGL3:FL) and pGL3-Basic EV (0.2 &#181;g) co-transfected with pPac0 and pPac-Sp1 (0.2 &#181;g) in <italic>Drosophila</italic> SL2 cells. (<bold>B</bold>) Western blot demonstrating overexpression of Sp1 from corresponding promoter lysates following transfection of HCT116 p53<sup>+/+</sup> cells with pN3-EV or pN3-Sp1 (0.2 &#181;g), anti-&#946;-actin was used to control for loading; relative luciferase of dUTPase promoter constructs co-transfected with both pN3-EV and pN3-Sp1 (0.2 &#181;g) in HCT116 p53<sup>+/+</sup> cells, numbers indicate fold-increase of pN3-Sp1 transfected cells compared to pN3-EV. Transfections were performed as outlined in &#8216;Experimental Procedures&#8217; Section. Histogram bars represent mean &#177; SEM of three independent promoter experiments. (<bold>C</bold>) Top: Western blot following transfection of HCT116 p53<sup>+/+</sup> cells with Lipofectamine only (Mock), 100 nM scrambled control siRNA (Scr) and 100 nM of Stealth<sup>TM</sup> DuoPak siRNA targeting Sp1 (Sp1) for 72 h and probed with anti-dUTPase and anti-Sp1. Anti-&#946;-actin was used to control for loading. Bottom: Relative luciferase activity of dUTPase full length promoter (pGL3:FL) transfected (0.2 &#181;g) into HCT116 p53<sup>+/+</sup> cells in the presence of scrambled control siRNA or Stealth<sup>TM</sup> DuoPak Sp1-targeted siRNA, histogram bars represent mean &#177; SEM of three independent promoter experiments. (<bold>D</bold>) Chromatin immunoprecipitation demonstrating <italic>in vivo</italic> association of E2F-1, Sp1 and Ac-H3 with the dUTPase promoter during normal cellular proliferation, visualized by semi-quantitative gel electrophoresis and qPCR using primers encompassing the E2F and Sp1 sites (&#8211;39 to &#8211;260) in the dUTPase promoter as indicated in Figure 1A. **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p>
###xml 1152 2937 1152 2907 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="51">The role of Sp1 in dUTPase gene expression. (<bold>A</bold>) Relative luciferase activity of dUTPase full-length promoter (pGL3:FL) and pGL3-Basic EV (0.2 &#181;g) co-transfected with pPac0 and pPac-Sp1 (0.2 &#181;g) in <italic>Drosophila</italic> SL2 cells. (<bold>B</bold>) Western blot demonstrating overexpression of Sp1 from corresponding promoter lysates following transfection of HCT116 p53<sup>+/+</sup> cells with pN3-EV or pN3-Sp1 (0.2 &#181;g), anti-&#946;-actin was used to control for loading; relative luciferase of dUTPase promoter constructs co-transfected with both pN3-EV and pN3-Sp1 (0.2 &#181;g) in HCT116 p53<sup>+/+</sup> cells, numbers indicate fold-increase of pN3-Sp1 transfected cells compared to pN3-EV. Transfections were performed as outlined in &#8216;Experimental Procedures&#8217; Section. Histogram bars represent mean &#177; SEM of three independent promoter experiments. (<bold>C</bold>) Top: Western blot following transfection of HCT116 p53<sup>+/+</sup> cells with Lipofectamine only (Mock), 100 nM scrambled control siRNA (Scr) and 100 nM of Stealth<sup>TM</sup> DuoPak siRNA targeting Sp1 (Sp1) for 72 h and probed with anti-dUTPase and anti-Sp1. Anti-&#946;-actin was used to control for loading. Bottom: Relative luciferase activity of dUTPase full length promoter (pGL3:FL) transfected (0.2 &#181;g) into HCT116 p53<sup>+/+</sup> cells in the presence of scrambled control siRNA or Stealth<sup>TM</sup> DuoPak Sp1-targeted siRNA, histogram bars represent mean &#177; SEM of three independent promoter experiments. (<bold>D</bold>) Chromatin immunoprecipitation demonstrating <italic>in vivo</italic> association of E2F-1, Sp1 and Ac-H3 with the dUTPase promoter during normal cellular proliferation, visualized by semi-quantitative gel electrophoresis and qPCR using primers encompassing the E2F and Sp1 sites (&#8211;39 to &#8211;260) in the dUTPase promoter as indicated in Figure 1A. **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption>
###xml 2937 2937 2907 2907 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn910f2"/>
###xml 1143 2937 1143 2907 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="51">The role of Sp1 in dUTPase gene expression. (<bold>A</bold>) Relative luciferase activity of dUTPase full-length promoter (pGL3:FL) and pGL3-Basic EV (0.2 &#181;g) co-transfected with pPac0 and pPac-Sp1 (0.2 &#181;g) in <italic>Drosophila</italic> SL2 cells. (<bold>B</bold>) Western blot demonstrating overexpression of Sp1 from corresponding promoter lysates following transfection of HCT116 p53<sup>+/+</sup> cells with pN3-EV or pN3-Sp1 (0.2 &#181;g), anti-&#946;-actin was used to control for loading; relative luciferase of dUTPase promoter constructs co-transfected with both pN3-EV and pN3-Sp1 (0.2 &#181;g) in HCT116 p53<sup>+/+</sup> cells, numbers indicate fold-increase of pN3-Sp1 transfected cells compared to pN3-EV. Transfections were performed as outlined in &#8216;Experimental Procedures&#8217; Section. Histogram bars represent mean &#177; SEM of three independent promoter experiments. (<bold>C</bold>) Top: Western blot following transfection of HCT116 p53<sup>+/+</sup> cells with Lipofectamine only (Mock), 100 nM scrambled control siRNA (Scr) and 100 nM of Stealth<sup>TM</sup> DuoPak siRNA targeting Sp1 (Sp1) for 72 h and probed with anti-dUTPase and anti-Sp1. Anti-&#946;-actin was used to control for loading. Bottom: Relative luciferase activity of dUTPase full length promoter (pGL3:FL) transfected (0.2 &#181;g) into HCT116 p53<sup>+/+</sup> cells in the presence of scrambled control siRNA or Stealth<sup>TM</sup> DuoPak Sp1-targeted siRNA, histogram bars represent mean &#177; SEM of three independent promoter experiments. (<bold>D</bold>) Chromatin immunoprecipitation demonstrating <italic>in vivo</italic> association of E2F-1, Sp1 and Ac-H3 with the dUTPase promoter during normal cellular proliferation, visualized by semi-quantitative gel electrophoresis and qPCR using primers encompassing the E2F and Sp1 sites (&#8211;39 to &#8211;260) in the dUTPase promoter as indicated in Figure 1A. **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption><graphic xlink:href="gkn910f2"/></fig>
###xml 429 439 <span type="species:ncbi:7227">Drosophila</span>
###xml 1357 1367 <span type="species:ncbi:7227">Drosophila</span>
Elevated intratumoral expression of Sp1 is reported to increase expression of genes that promote tumor processes including progression and angiogenesis (33). It is therefore plausible that dysregulation of Sp1 may contribute to increased expression of dUTPase that is observed in tumor tissues. In order to accurately determine the contribution of Sp1 to basal promoter activity, we utilized the well-characterized Sp1-deficient Drosophila SL2 cells as a useful model for analyzing the influence of Sp1-driven promoters in an Sp1-deficient background (32). The pGL3-Basic promoterless vector was subsequently co-transfected with the EV and pPac-Sp1 expression construct, both resulting in minimal luciferase activity. Co-transfection of the pGL3:FL with pPac0 resulted in no significant promoter activity when compared to the co-transfection with pGL3-Basic. However, co-transfection of pGL3:FL and pPac-Sp1 resulted in a 45-fold increase in luciferase activity (Figure 2A). These data demonstrate that the dUTPase promoter requires Sp1 for basal activity and is also highly responsive to Sp1-mediated transcription in an Sp1-deficient model. Figure 2.The role of Sp1 in dUTPase gene expression. (A) Relative luciferase activity of dUTPase full-length promoter (pGL3:FL) and pGL3-Basic EV (0.2 microg) co-transfected with pPac0 and pPac-Sp1 (0.2 microg) in Drosophila SL2 cells. (B) Western blot demonstrating overexpression of Sp1 from corresponding promoter lysates following transfection of HCT116 p53+/+ cells with pN3-EV or pN3-Sp1 (0.2 microg), anti-beta-actin was used to control for loading; relative luciferase of dUTPase promoter constructs co-transfected with both pN3-EV and pN3-Sp1 (0.2 microg) in HCT116 p53+/+ cells, numbers indicate fold-increase of pN3-Sp1 transfected cells compared to pN3-EV. Transfections were performed as outlined in 'Experimental Procedures' Section. Histogram bars represent mean +/- SEM of three independent promoter experiments. (C) Top: Western blot following transfection of HCT116 p53+/+ cells with Lipofectamine only (Mock), 100 nM scrambled control siRNA (Scr) and 100 nM of StealthTM DuoPak siRNA targeting Sp1 (Sp1) for 72 h and probed with anti-dUTPase and anti-Sp1. Anti-beta-actin was used to control for loading. Bottom: Relative luciferase activity of dUTPase full length promoter (pGL3:FL) transfected (0.2 microg) into HCT116 p53+/+ cells in the presence of scrambled control siRNA or StealthTM DuoPak Sp1-targeted siRNA, histogram bars represent mean +/- SEM of three independent promoter experiments. (D) Chromatin immunoprecipitation demonstrating in vivo association of E2F-1, Sp1 and Ac-H3 with the dUTPase promoter during normal cellular proliferation, visualized by semi-quantitative gel electrophoresis and qPCR using primers encompassing the E2F and Sp1 sites (-39 to -260) in the dUTPase promoter as indicated in Figure 1A. **P < 0.01, ***P < 0.001; NS, not significant.
###end p 50
###begin p 51
###xml 45 46 45 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 205 215 197 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 228 229 220 221 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 352 355 344 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 569 572 550 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 821 822 800 801 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 878 881 857 860 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 978 980 957 959 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 1234 1237 1206 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1297 1299 1269 1271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 1409 1410 1379 1380 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1456 1463 1426 1433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1741 1742 1711 1712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1754 1755 1724 1725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 205 215 <span type="species:ncbi:7227">Drosophila</span>
The role of Sp1 in dUTPase gene expression. (A) Relative luciferase activity of dUTPase full-length promoter (pGL3:FL) and pGL3-Basic EV (0.2 microg) co-transfected with pPac0 and pPac-Sp1 (0.2 microg) in Drosophila SL2 cells. (B) Western blot demonstrating overexpression of Sp1 from corresponding promoter lysates following transfection of HCT116 p53+/+ cells with pN3-EV or pN3-Sp1 (0.2 microg), anti-beta-actin was used to control for loading; relative luciferase of dUTPase promoter constructs co-transfected with both pN3-EV and pN3-Sp1 (0.2 microg) in HCT116 p53+/+ cells, numbers indicate fold-increase of pN3-Sp1 transfected cells compared to pN3-EV. Transfections were performed as outlined in 'Experimental Procedures' Section. Histogram bars represent mean +/- SEM of three independent promoter experiments. (C) Top: Western blot following transfection of HCT116 p53+/+ cells with Lipofectamine only (Mock), 100 nM scrambled control siRNA (Scr) and 100 nM of StealthTM DuoPak siRNA targeting Sp1 (Sp1) for 72 h and probed with anti-dUTPase and anti-Sp1. Anti-beta-actin was used to control for loading. Bottom: Relative luciferase activity of dUTPase full length promoter (pGL3:FL) transfected (0.2 microg) into HCT116 p53+/+ cells in the presence of scrambled control siRNA or StealthTM DuoPak Sp1-targeted siRNA, histogram bars represent mean +/- SEM of three independent promoter experiments. (D) Chromatin immunoprecipitation demonstrating in vivo association of E2F-1, Sp1 and Ac-H3 with the dUTPase promoter during normal cellular proliferation, visualized by semi-quantitative gel electrophoresis and qPCR using primers encompassing the E2F and Sp1 sites (-39 to -260) in the dUTPase promoter as indicated in Figure 1A. **P < 0.01, ***P < 0.001; NS, not significant.
###end p 51
###begin p 52
###xml 134 137 134 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 379 387 379 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1187 1195 1187 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
Having confirmed that the dUTPase promoter is responsive to Sp1 in an Sp1-null background, we extended these studies to the HCT116 p53+/+ cells and tested the effect of Sp1 overexpression on the dUTPase promoter. Western blot analysis demonstrated a physiologically relevant 2-fold increase in Sp1 protein expression following transfection with the pN3-Sp1 expression construct (Figure 2B). Importantly, Sp1 overexpression did not induce the pGL3-Basic control discounting any possible non-specific effects. Co-transfection of the pGL3:FL with the pN3-Sp1 construct resulted in a 5.6-fold increase in luciferase activity compared to the pN3-EV. We also tested the Sp1-responsiveness of the promoter truncations and demonstrate that the pGL3:608 truncation is significantly less responsive to Sp1-mediated activation than the pGL3:FL (3.9-fold compared to 5.6-fold respectively), further suggesting that the 5' region from -608 to -1231 may contain some Sp1-responsive elements. In addition, the pGL3:65 containing only the E2F site was induced 1.8-fold by overexpression of Sp1 suggesting that Sp1 may also mediate dUTPase promoter activation indirectly through E2F consensus sequences (Figure 2B). However, Sp1 overexpression resulted in only a modest increase in luciferase activity of the pGL3:Sp1Delta which did not reach statistical significance (data not shown). These data would suggest that the effects of Sp1 overexpression were primarily limited to the identified triple Sp1 sites.
###end p 52
###begin p 53
###xml 72 74 72 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 559 562 559 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 570 578 570 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
To confirm the role of Sp1 in dUTPase transcription, we utilized StealthTM RNAi employing two siRNA duplexes targeting the Sp1 mRNA. Transfection with the Sp1-targeted siRNA resulted in knockdown of Sp1 as measured by western blotting at 72 h. Importantly dUTPase protein expression was also markedly reduced at 72 h in cells transfected with Sp1-targeted siRNA when compared to mock- and scrambled control-transfected cells. In addition, depletion of Sp1 also significantly attenuated the activity of the dUTPase full-length promoter by >5-fold in HCT116 p53+/+ cells (Figure 2C).
###end p 53
###begin p 54
###xml 78 85 78 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 638 646 638 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 769 776 769 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 410 416 <span type="species:ncbi:9986">rabbit</span>
To further confirm that Sp1 and E2F play a role in driving dUTPase expression in vivo we utilized a highly sensitive and quantitative approach combining ChIP with qPCR and a primer set spanning the triple Sp1 and E2F sites in the dUTPase promoter. We successfully identified Sp1 and E2F-1 transcription factors as enriched 11- and 21.5-fold, respectively, at the dUTPase promoter when compared to non-specific rabbit IgG controls and normalized to input DNA. Acetyl-H3 (Ac-H3), an indicator of active gene transcription was employed as a positive control and demonstrated a highly significant 200-fold enrichment at the dUTPase promoter (Figure 2D). These data provide the first direct evidence that both Sp1 and E2F-1 are actively associated with the dUTPase promoter in vivo and that this region is subject to significant histone acetylation.
###end p 54
###begin title 55
Ectopic p53 represses dUTPase promoter activity
###end title 55
###begin p 56
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 658 660 658 660 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 699 702 699 702 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 941 943 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1037 1040 1035 1038 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1048 1051 1046 1049 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1225 1228 1223 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1270 1273 1268 1271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1295 1303 1293 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 736 741 <span type="species:ncbi:9606">human</span>
###xml 917 922 <span type="species:ncbi:10090">mouse</span>
Several reports have identified dUTPase as repressed following ectopic expression or induction of p53 (21,22) and a p53-mutant transactivation gene target (24). Mutations in the p53 tumor suppressor gene are reported in a wide variety of cancers and in >50% of colon cancers (35). Significant evidence exists suggesting that tumor p53 status has direct impact on gene expression, tumor progression and response to chemotherapy (36). Given the critical nature of dUTPase expression in modulating response to the TS-inhibitor class of chemotherapeutics, we sought to test whether dUTPase expression is modulated by ectopic expression of both wild-type p53 (p53WT) and the hotspot R175H p53 mutant (p53MUT). This is one of the most common human tumor-derived mutant p53 proteins, harboring an Arg-->His amino-acid substitution resulting in a dominant gain-of-function and has been reported to induce dUTPase in p53 null mouse fibroblast cells (24). We generated overexpression constructs using the pCI-Neo vector and utilized the HCT116 p53+/+ and p53-/- isogenic colon cancer cell lines to determine the precise contribution of p53 on dUTPase promoter activity. For confirmation purposes, p53 expression was verified in the p53+/+ cells and absence noted in the HCT116 p53-/- by western blotting (Figure 3A).
###end p 56
###begin p 57
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 112 114 112 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 130 133 130 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 338 341 334 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 437 439 433 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 455 458 451 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 634 642 630 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 694 696 690 692 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 866 869 862 865 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 970 978 966 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1043 1046 1039 1042 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1231 1234 1227 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1284 1286 1280 1282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1306 1309 1302 1305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 1311 1319 1307 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1370 1372 1366 1368 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1488 1496 1484 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1556 1559 1552 1555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 1660 1668 1656 1664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1892 1901 1888 1897 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 2037 2040 2033 2036 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2086 2089 2082 2085 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2107 2110 2103 2106 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2391 2393 2384 2386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 2409 2412 2402 2405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 2436 2439 2425 2428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2452 2453 2441 2442 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2586 2588 2571 2573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 2604 2607 2589 2592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 2631 2634 2612 2615 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2647 2648 2628 2629 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2796 2798 2777 2779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 2814 2817 2795 2798 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 2848 2851 2825 2828 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2864 2865 2841 2842 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2998 3000 2971 2973 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 3016 3019 2989 2992 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 3043 3046 3012 3015 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 3224 3225 3191 3192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 3236 3237 3203 3204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 3249 3250 3216 3217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1901 3259 1897 3226 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="58">Ectopic p53 represses dUTPase promoter activity. (A) Western blot probed with anti-p53, anti-p21 confirming p53 expression in HCT116 p53<sup>+/+</sup> cells and absence of expression in HCT116 p53<sup>&#8211;/&#8211;</sup> cells. HCT116 p21<sup>&#8211;/&#8211;</sup> cells were included in this Western analysis for direct comparative purposes, anti-&#946;-actin was used to control for loading. (B) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with of pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>&#8211;/&#8211;</sup> cell line. (<bold>C</bold>) Fold-change in luciferase activity of dUTPase full-length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>&#8211;/&#8211;</sup> cell line. (<bold>D</bold>) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the HCT116 p53<sup>+/+</sup> cell line. (<bold>E</bold>) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>+/+</sup> cell line. All transfections were performed as outlined in &#8216;Experimental Procedures&#8217; Section. Histogram bars represents mean &#177; SEM of three independent promoter experiments. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p>
###xml 1901 3259 1897 3226 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="58">Ectopic p53 represses dUTPase promoter activity. (A) Western blot probed with anti-p53, anti-p21 confirming p53 expression in HCT116 p53<sup>+/+</sup> cells and absence of expression in HCT116 p53<sup>&#8211;/&#8211;</sup> cells. HCT116 p21<sup>&#8211;/&#8211;</sup> cells were included in this Western analysis for direct comparative purposes, anti-&#946;-actin was used to control for loading. (B) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with of pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>&#8211;/&#8211;</sup> cell line. (<bold>C</bold>) Fold-change in luciferase activity of dUTPase full-length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>&#8211;/&#8211;</sup> cell line. (<bold>D</bold>) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the HCT116 p53<sup>+/+</sup> cell line. (<bold>E</bold>) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>+/+</sup> cell line. All transfections were performed as outlined in &#8216;Experimental Procedures&#8217; Section. Histogram bars represents mean &#177; SEM of three independent promoter experiments. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption>
###xml 3259 3259 3226 3226 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn910f3"/>
###xml 1892 3259 1888 3226 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="58">Ectopic p53 represses dUTPase promoter activity. (A) Western blot probed with anti-p53, anti-p21 confirming p53 expression in HCT116 p53<sup>+/+</sup> cells and absence of expression in HCT116 p53<sup>&#8211;/&#8211;</sup> cells. HCT116 p21<sup>&#8211;/&#8211;</sup> cells were included in this Western analysis for direct comparative purposes, anti-&#946;-actin was used to control for loading. (B) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with of pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>&#8211;/&#8211;</sup> cell line. (<bold>C</bold>) Fold-change in luciferase activity of dUTPase full-length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>&#8211;/&#8211;</sup> cell line. (<bold>D</bold>) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the HCT116 p53<sup>+/+</sup> cell line. (<bold>E</bold>) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p53<sup>+/+</sup> cell line. All transfections were performed as outlined in &#8216;Experimental Procedures&#8217; Section. Histogram bars represents mean &#177; SEM of three independent promoter experiments. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="gkn910f3"/></fig>
To eliminate any effects from endogenous p53, we utilized the HCT116 p53-/- cells. A titration using pCI-Neo:p53WT and pCI-Neo:p53MUT constructs was performed and indicated that a vector concentration of 0.2 microg per transfection resulted in a physiological relevant increase in p53 protein consistent with the level of induction in p53+/+ cells at 24 h post-DNA damage (data not shown). Co-transfection of the pGL3:FL with pCI-Neo:p53WT and pCI-Neo:p53MUT induced a physiologically relevant expression of the respective p53 proteins detected by western blotting with the pCI-Neo EV control demonstrating no detectable p53 protein (Figure 3B). Co-transfection of the pGL3:FL with pCI-Neo: p53WT resulted in a 7-fold reduction in promoter activity when compared to the pGL3:FL co-transfected with pCI-Neo EV. In contrast, co-transfection of pGL3:FL with pCI-Neo:p53MUT resulted in a 1.9-fold increase in promoter activity when compared to the corresponding EV control (Figure 3C). We then analyzed the effects of p53 overexpression in the p53+/+ cells which contain endogenous levels of p53 protein. Western blot analysis confirmed detection of basal p53 and similar levels of p53 overexpression in these cells compared to the p53-/- cells following transfection with the pCI-Neo:p53WT and and pCI-Neo:p53MUT (Figure 3D). Co-transfection of the pGL3:FL with pCI-Neo:p53WT resulted in a 2.6-fold reduction in promoter activity when compared to the pGL3:FL co-transfected with pCI-Neo EV (Figure 3E). In contrast, co-transfection of pGL3:FL with pCI-Neo:p53MUT resulted in a 3.8-fold increase in promoter activity when compared to the corresponding EV control (Figure 3E). These data indicate that ectopic expression of wild-type p53 can repress dUTPase promoter activity and that ectopic p53 mutant expression can induce dUTPase promoter activity in the HCT116 p53 isogenic cell-line models. Figure 3.Ectopic p53 represses dUTPase promoter activity. (A) Western blot probed with anti-p53, anti-p21 confirming p53 expression in HCT116 p53+/+ cells and absence of expression in HCT116 p53-/- cells. HCT116 p21-/- cells were included in this Western analysis for direct comparative purposes, anti-beta-actin was used to control for loading. (B) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with of pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p53-/- cell line. (C) Fold-change in luciferase activity of dUTPase full-length (pGL3:FL) promoter construct (0.2 microg) co-transfected with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p53-/- cell line. (D) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the HCT116 p53+/+ cell line. (E) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 microg) co-transfected with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p53+/+ cell line. All transfections were performed as outlined in 'Experimental Procedures' Section. Histogram bars represents mean +/- SEM of three independent promoter experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
###end p 57
###begin p 58
###xml 136 139 136 139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 185 188 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 206 209 206 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 490 492 487 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 508 511 505 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 535 538 528 531 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 551 552 544 545 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 685 687 674 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 703 706 692 695 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 730 733 715 718 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 746 747 731 732 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 895 897 880 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 913 916 898 901 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 947 950 928 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 963 964 944 945 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1097 1099 1074 1076 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1115 1118 1092 1095 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 1142 1145 1115 1118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1323 1324 1294 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1335 1336 1306 1307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1348 1349 1319 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Ectopic p53 represses dUTPase promoter activity. (A) Western blot probed with anti-p53, anti-p21 confirming p53 expression in HCT116 p53+/+ cells and absence of expression in HCT116 p53-/- cells. HCT116 p21-/- cells were included in this Western analysis for direct comparative purposes, anti-beta-actin was used to control for loading. (B) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with of pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p53-/- cell line. (C) Fold-change in luciferase activity of dUTPase full-length (pGL3:FL) promoter construct (0.2 microg) co-transfected with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p53-/- cell line. (D) Western blot demonstrating equivalent ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the HCT116 p53+/+ cell line. (E) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 microg) co-transfected with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p53+/+ cell line. All transfections were performed as outlined in 'Experimental Procedures' Section. Histogram bars represents mean +/- SEM of three independent promoter experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
###end p 58
###begin title 59
The effects of DNA damage-induced p53 on dUTPase gene expression
###end title 59
###begin p 60
###xml 177 179 177 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 187 190 187 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 727 730 727 730 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 738 746 738 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1090 1098 1086 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1231 1234 1227 1230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1242 1245 1238 1241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1356 1359 1352 1355 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1408 1411 1404 1407 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1591 1594 1583 1586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1694 1697 1686 1689 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1719 1727 1711 1719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1895 1904 1887 1896 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 1971 1972 1963 1964 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2226 2227 2203 2204 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2270 2273 2247 2250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2281 2284 2258 2261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2729 2730 2697 2698 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2742 2743 2710 2711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1904 2773 1896 2741 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="61">The effects of DNA damage-induced p53 on dUTPase gene expression. (<bold>A</bold>) Representative western blot showing timecourse following treatment with the chemotherapeutic agents 5-FU (5 &#181;M), FUdR (1 &#181;M) and oxaliplatin (0.5 &#181;M), probed with anti-p53 and anti-dUTPase, anti-&#946;-actin was used to control for loading. (<bold>B</bold>) Representative western blot in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 48 and 72 h. Membrane was probed with anti-p53, anti-dUTPase and anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls set at 100%, bars represents mean &#177; SEM from two replicates. **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p>
###xml 1904 2773 1896 2741 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="61">The effects of DNA damage-induced p53 on dUTPase gene expression. (<bold>A</bold>) Representative western blot showing timecourse following treatment with the chemotherapeutic agents 5-FU (5 &#181;M), FUdR (1 &#181;M) and oxaliplatin (0.5 &#181;M), probed with anti-p53 and anti-dUTPase, anti-&#946;-actin was used to control for loading. (<bold>B</bold>) Representative western blot in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 48 and 72 h. Membrane was probed with anti-p53, anti-dUTPase and anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls set at 100%, bars represents mean &#177; SEM from two replicates. **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption>
###xml 2773 2773 2741 2741 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn910f4"/>
###xml 1895 2773 1887 2741 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="61">The effects of DNA damage-induced p53 on dUTPase gene expression. (<bold>A</bold>) Representative western blot showing timecourse following treatment with the chemotherapeutic agents 5-FU (5 &#181;M), FUdR (1 &#181;M) and oxaliplatin (0.5 &#181;M), probed with anti-p53 and anti-dUTPase, anti-&#946;-actin was used to control for loading. (<bold>B</bold>) Representative western blot in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 48 and 72 h. Membrane was probed with anti-p53, anti-dUTPase and anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls set at 100%, bars represents mean &#177; SEM from two replicates. **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption><graphic xlink:href="gkn910f4"/></fig>
dUTPase expression is reported to be an important determinant of sensitivity to chemotherapeutic agents that target TS. Having determined that ectopic overexpression of both p53WT and p53MUT have direct effects on the dUTPase promoter we sought to determine if DNA-damage-induced p53 can directly modulate dUTPase protein expression. We utilized the TS-targeted chemotherapeutic agents 5-FU and FUdR, both of which are reported to activate p53. In addition, we utilized oxaliplatin, a non-TS-directed DNA-damaging agent and the primary 5-FU combination partner for the treatment of colorectal cancer (37). Western blotting confirmed the induction of p53 at 24-72 h in response to 5-FU, FUdR and oxaliplatin treatment in the p53+/+ cells (Figure 4A). In response to 5-FU and FUdR, dUTPase protein expression remained unchanged until 72 h post-treatment where levels were only moderately reduced. Unexpectedly, 0.5 microM oxaliplatin treatment significantly downregulated dUTPase at 48 h post-treatment and by 72 h dUTPase was further reduced to undetectable levels by western blot analysis (Figure 4A). To investigate the contribution of p53 expression to the novel observation that oxaliplatin downregulates dUTPase, the HCT116 p53+/+ and p53-/- isogenic cell lines were utilized. Western blot analysis demonstrated that p53 was markedly induced in the p53+/+ cells but was not detected or induced in the p53-/- cells following treatment with 1 microM oxaliplatin. In response to oxaliplatin, dUTPase expression and enzymatic activity was significantly downregulated 2- and 5-fold in the p53+/+ cells at 48 and 72 h, respectively. No modulation of expression or activity was detected in the p53-/- cells at 48 or 72 h (Figure 4B). This data suggests that p53 or a downstream p53-target pathway is responsible for the downregulation of dUTPase protein expression following oxaliplatin treatment. Figure 4.The effects of DNA damage-induced p53 on dUTPase gene expression. (A) Representative western blot showing timecourse following treatment with the chemotherapeutic agents 5-FU (5 microM), FUdR (1 microM) and oxaliplatin (0.5 microM), probed with anti-p53 and anti-dUTPase, anti-beta-actin was used to control for loading. (B) Representative western blot in HCT116 p53+/+ and p53-/- isogenic cells following treatment with 1 microM oxaliplatin for 48 and 72 h. Membrane was probed with anti-p53, anti-dUTPase and anti-beta-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls set at 100%, bars represents mean +/- SEM from two replicates. **P < 0.01, ***P < 0.001; NS, not significant.
###end p 60
###begin p 61
###xml 67 68 67 68 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 322 323 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 366 369 351 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 377 380 362 365 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 825 826 801 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 838 839 814 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The effects of DNA damage-induced p53 on dUTPase gene expression. (A) Representative western blot showing timecourse following treatment with the chemotherapeutic agents 5-FU (5 microM), FUdR (1 microM) and oxaliplatin (0.5 microM), probed with anti-p53 and anti-dUTPase, anti-beta-actin was used to control for loading. (B) Representative western blot in HCT116 p53+/+ and p53-/- isogenic cells following treatment with 1 microM oxaliplatin for 48 and 72 h. Membrane was probed with anti-p53, anti-dUTPase and anti-beta-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls set at 100%, bars represents mean +/- SEM from two replicates. **P < 0.01, ***P < 0.001; NS, not significant.
###end p 61
###begin title 62
p53-mediated downregulation of dUTPase by oxaliplatin is induced through a transcriptional mechanism
###end title 62
###begin p 63
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 585 588 585 588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 596 599 596 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 666 669 666 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 799 802 799 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 810 818 810 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 1098 1101 1098 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1109 1112 1109 1112 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1209 1218 1209 1218 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 1321 1322 1321 1322 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1450 1453 1446 1449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1461 1464 1457 1460 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1594 1595 1586 1587 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1640 1643 1632 1635 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1651 1654 1643 1646 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1853 1854 1839 1840 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1894 1897 1880 1883 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1905 1908 1891 1894 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2099 2100 2079 2080 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2720 2721 2683 2684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2733 2734 2696 2697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1218 2764 1218 2727 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="64">p53-mediated downregulation of dUTPase by oxaliplatin is induced through a transcriptional mechanism. (<bold>A</bold>) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) following transfection (0.2 &#181;g) in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells and treatment with 1 &#181;M oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1. (<bold>B</bold>) qPCR analysis of dUTPase mRNA in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 24 and 48 h compared to time-matched controls set at 100%, histogram bars represents mean &#177; SEM of three independent experiments. (<bold>C</bold>) qPCR analysis of TS mRNA in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 24 h compared to time-matched control set at 100%, histogram bars represents mean &#177; SEM of three independent experiments. (<bold>D</bold>) Western blot following transfection of HCT116 pTet-off cells with pTre-Tight:DUT-N (1 &#181;g) showing increased expression of dUTPase in the absence of DOX (induced) and basal expression in the presence of 0.5 &#181;g/ml DOX (basal) and subsequent treatment with 1 &#181;M oxaliplatin for 48 h. Anti-p53 was used to confirm p53 induction and anti-&#946;-actin to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of untreated control set at 100%, bars represents mean &#177; SEM from two independent replicates. *<italic>P</italic> &lt; 0.05, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p>
###xml 1218 2764 1218 2727 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="64">p53-mediated downregulation of dUTPase by oxaliplatin is induced through a transcriptional mechanism. (<bold>A</bold>) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) following transfection (0.2 &#181;g) in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells and treatment with 1 &#181;M oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1. (<bold>B</bold>) qPCR analysis of dUTPase mRNA in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 24 and 48 h compared to time-matched controls set at 100%, histogram bars represents mean &#177; SEM of three independent experiments. (<bold>C</bold>) qPCR analysis of TS mRNA in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 24 h compared to time-matched control set at 100%, histogram bars represents mean &#177; SEM of three independent experiments. (<bold>D</bold>) Western blot following transfection of HCT116 pTet-off cells with pTre-Tight:DUT-N (1 &#181;g) showing increased expression of dUTPase in the absence of DOX (induced) and basal expression in the presence of 0.5 &#181;g/ml DOX (basal) and subsequent treatment with 1 &#181;M oxaliplatin for 48 h. Anti-p53 was used to confirm p53 induction and anti-&#946;-actin to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of untreated control set at 100%, bars represents mean &#177; SEM from two independent replicates. *<italic>P</italic> &lt; 0.05, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption>
###xml 2764 2764 2727 2727 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn910f5"/>
###xml 1209 2764 1209 2727 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="64">p53-mediated downregulation of dUTPase by oxaliplatin is induced through a transcriptional mechanism. (<bold>A</bold>) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) following transfection (0.2 &#181;g) in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells and treatment with 1 &#181;M oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1. (<bold>B</bold>) qPCR analysis of dUTPase mRNA in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 24 and 48 h compared to time-matched controls set at 100%, histogram bars represents mean &#177; SEM of three independent experiments. (<bold>C</bold>) qPCR analysis of TS mRNA in HCT116 p53<sup>+/+</sup> and p53<sup>&#8211;/&#8211;</sup> isogenic cells following treatment with 1 &#181;M oxaliplatin for 24 h compared to time-matched control set at 100%, histogram bars represents mean &#177; SEM of three independent experiments. (<bold>D</bold>) Western blot following transfection of HCT116 pTet-off cells with pTre-Tight:DUT-N (1 &#181;g) showing increased expression of dUTPase in the absence of DOX (induced) and basal expression in the presence of 0.5 &#181;g/ml DOX (basal) and subsequent treatment with 1 &#181;M oxaliplatin for 48 h. Anti-p53 was used to confirm p53 induction and anti-&#946;-actin to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of untreated control set at 100%, bars represents mean &#177; SEM from two independent replicates. *<italic>P</italic> &lt; 0.05, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption><graphic xlink:href="gkn910f5"/></fig>
It has been reported that proteins involved in cell-cycle progression and DNA synthesis are acutely downregulated in an atypical manner following exit from cell-cycle phases or following induction of DNA damage-induced cell cycle arrest by mechanisms such as ubiquitination and proteasomal degradation (38,39). To confirm that the acute oxaliplatin-induced downregulation of dUTPase protein was due to direct transcriptional repression and not post-transcriptional mechanisms or protein stability, we transfected the dUTPase full-length (pGL3:FL) promoter construct into the HCT116 p53+/+ and p53-/- isogenic cells and analyzed the effects of oxaliplatin. In the p53+/+ cells, oxaliplatin potently attenuated activity of the pGL3:FL promoter by 5-fold with only a modest reduction of 1.5-fold in p53-/- cells (Figure 5A). Mithramycin A, a specific inhibitor of Sp1-driven gene expression that functions by binding to, and inhibiting transcription from GC-rich promoters (33,34) was utilized as a positive control and potently attenuated dUTPase promoter activity by 3.5- and 10-fold in both the p53+/+ and p53-/- isogenic cells respectively, consistent with inhibiting Sp1-mediated dUTPase promoter activity. Figure 5.p53-mediated downregulation of dUTPase by oxaliplatin is induced through a transcriptional mechanism. (A) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) following transfection (0.2 microg) in HCT116 p53+/+ and p53-/- isogenic cells and treatment with 1 microM oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1. (B) qPCR analysis of dUTPase mRNA in HCT116 p53+/+ and p53-/- isogenic cells following treatment with 1 microM oxaliplatin for 24 and 48 h compared to time-matched controls set at 100%, histogram bars represents mean +/- SEM of three independent experiments. (C) qPCR analysis of TS mRNA in HCT116 p53+/+ and p53-/- isogenic cells following treatment with 1 microM oxaliplatin for 24 h compared to time-matched control set at 100%, histogram bars represents mean +/- SEM of three independent experiments. (D) Western blot following transfection of HCT116 pTet-off cells with pTre-Tight:DUT-N (1 microg) showing increased expression of dUTPase in the absence of DOX (induced) and basal expression in the presence of 0.5 microg/ml DOX (basal) and subsequent treatment with 1 microM oxaliplatin for 48 h. Anti-p53 was used to confirm p53 induction and anti-beta-actin to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of untreated control set at 100%, bars represents mean +/- SEM from two independent replicates. *P < 0.05, ***P < 0.001; NS, not significant.
###end p 63
###begin p 64
###xml 103 104 103 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 232 235 228 231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 243 246 239 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 376 377 368 369 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 422 425 414 417 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 433 436 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 635 636 621 622 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 676 679 662 665 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 687 690 673 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 881 882 861 862 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1502 1503 1465 1466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1515 1516 1478 1479 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
p53-mediated downregulation of dUTPase by oxaliplatin is induced through a transcriptional mechanism. (A) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) following transfection (0.2 microg) in HCT116 p53+/+ and p53-/- isogenic cells and treatment with 1 microM oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1. (B) qPCR analysis of dUTPase mRNA in HCT116 p53+/+ and p53-/- isogenic cells following treatment with 1 microM oxaliplatin for 24 and 48 h compared to time-matched controls set at 100%, histogram bars represents mean +/- SEM of three independent experiments. (C) qPCR analysis of TS mRNA in HCT116 p53+/+ and p53-/- isogenic cells following treatment with 1 microM oxaliplatin for 24 h compared to time-matched control set at 100%, histogram bars represents mean +/- SEM of three independent experiments. (D) Western blot following transfection of HCT116 pTet-off cells with pTre-Tight:DUT-N (1 microg) showing increased expression of dUTPase in the absence of DOX (induced) and basal expression in the presence of 0.5 microg/ml DOX (basal) and subsequent treatment with 1 microM oxaliplatin for 48 h. Anti-p53 was used to confirm p53 induction and anti-beta-actin to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of untreated control set at 100%, bars represents mean +/- SEM from two independent replicates. *P < 0.05, ***P < 0.001; NS, not significant.
###end p 64
###begin p 65
###xml 111 113 111 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 294 297 294 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 493 496 489 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 634 642 630 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 751 754 747 750 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 762 765 758 761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 924 927 920 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 935 938 931 934 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 945 953 941 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
To further investigate the role of p53 in the transcriptional downregulation of dUTPase, we employed the PlexorTM multiplex qPCR platform to simultaneously analyze mRNA expression of both dUTPase and an additional S-phase gene and chemotherapeutic target TS. Analysis of dUTPase mRNA in the p53+/+ cells demonstrated that following treatment with 1 microM oxaliplatin, dUTPase mRNA was downregulated 2.5- and >3-fold at 24 and 48 h when compared to respective time-matched controls. In the p53-/- cells, dUTPase mRNA was not significantly modulated by oxaliplatin at 24 or 48 h when compared to their respective time-matched control (Figure 5B). Simultaneous analysis of TS mRNA demonstrated a modest but significant downregulation at 24 h in both p53+/+ and p53-/- cells when compared to the 24 h time-matched control. The oxaliplatin-induced downregulation of TS was not statistically significant different between the p53+/+ and p53-/-cells (Figure 5C). These data confirm that p53 expression plays a significant role in the oxaliplatin-induced transcriptional suppression of dUTPase mRNA but not TS mRNA.
###end p 65
###begin p 66
###xml 1148 1156 1136 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 246 249 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 920 923 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
To eliminate the possibility that dUTPase is a target for atypical protein turnover as a result of oxaliplatin-induced cell-cycle arrest, we overexpressed dUTPase using the pTre-Tight:DUT-N construct under the control of a DOX-repressive minimal CMV promoter and treated cells with oxaliplatin and analyzed dUTPase protein expression and catalytic activity. Following overexpression, dUTPase protein and enzyme activity was increased approximately 4-fold in the absence of DOX when compared to an identical transfection in the presence of 0.5 microg/ml DOX where ectopic expression was repressed. When cells with basal dUTPase expression were treated with 1 microM oxaliplatin for 48 h, accumulation of p53 was confirmed and a >2-fold downregulation in dUTPase protein and activity was observed compared to the respective untreated control by western blot analysis. Cells overexpressing dUTPase from the ectopic minimal CMV promoter also demonstrated p53 accumulation following oxaliplatin treatment, with dUTPase expression levels and catalytic activity demonstrating no significant difference in the presence and absence of 1 microM oxaliplatin (Figure 5D). These data suggest that dUTPase protein expressed from the ectopic promoter was not a target for atypical turnover, decreased stability or transcriptional suppression by oxaliplatin treatment.
###end p 66
###begin title 67
p53-mediated downregulation of dUTPase does not require p21
###end title 67
###begin p 68
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 207 210 207 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 232 234 232 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 497 505 497 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 603 606 603 606 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 614 617 614 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 667 669 667 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 685 688 685 688 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 690 698 690 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 888 890 888 890 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1006 1009 1006 1009 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 1105 1108 1105 1108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1116 1124 1116 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1128 1137 1128 1137 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 1198 1200 1198 1200 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A</bold>
###xml 1377 1379 1377 1379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1395 1398 1395 1398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 1422 1425 1418 1421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1438 1439 1434 1435 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1572 1574 1564 1566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1590 1593 1582 1585 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 1617 1620 1605 1608 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1633 1634 1621 1622 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1857 1860 1837 1840 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2090 2091 2068 2069 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2143 2146 2121 2124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2255 2256 2229 2230 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 2284 2287 2258 2261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 2725 2726 2690 2691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2737 2738 2702 2703 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2750 2751 2715 2716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1137 2760 1137 2725 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="69">p53-mediated downregulation of dUTPase does not require p21. <bold>(A</bold>) Western blot demonstrating equivalent and physiologically relevant ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p21<sup>&#8211;/&#8211;</sup> cell line. (<bold>B</bold>) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p21<sup>&#8211;/&#8211;</sup> cell line. (<bold>C</bold>) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) (0.2 &#181;g) following treatment with 1 &#181;M oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1 in HCT116 p21<sup>&#8211;/&#8211;</sup> cells. All histogram bars represents mean &#177; SEM of three independent promoter experiments, transfections were performed as outlined in &#8216;Experimental Procedures.&#8217; Numbers on histograms indicate fold-change compared to pGL3:FL. (<bold>D</bold>) qPCR analysis of dUTPase and TS mRNA in HCT116 p21<sup>&#8211;/&#8211;</sup> cells following treatment with 1 &#181;M oxaliplatin for 24 h compared to time-matched control set at 100%. (<bold>E</bold>) Western blot in HCT116 p21<sup>&#8211;/&#8211;</sup> cells following treatment with 1 &#181;M oxaliplatin for 48 h. Membrane was probed with anti-p53 and anti-dUTPase, anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls. Histogram bars represents mean &#177; SEM from two independent replicates, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p>
###xml 1137 2760 1137 2725 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="69">p53-mediated downregulation of dUTPase does not require p21. <bold>(A</bold>) Western blot demonstrating equivalent and physiologically relevant ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p21<sup>&#8211;/&#8211;</sup> cell line. (<bold>B</bold>) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p21<sup>&#8211;/&#8211;</sup> cell line. (<bold>C</bold>) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) (0.2 &#181;g) following treatment with 1 &#181;M oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1 in HCT116 p21<sup>&#8211;/&#8211;</sup> cells. All histogram bars represents mean &#177; SEM of three independent promoter experiments, transfections were performed as outlined in &#8216;Experimental Procedures.&#8217; Numbers on histograms indicate fold-change compared to pGL3:FL. (<bold>D</bold>) qPCR analysis of dUTPase and TS mRNA in HCT116 p21<sup>&#8211;/&#8211;</sup> cells following treatment with 1 &#181;M oxaliplatin for 24 h compared to time-matched control set at 100%. (<bold>E</bold>) Western blot in HCT116 p21<sup>&#8211;/&#8211;</sup> cells following treatment with 1 &#181;M oxaliplatin for 48 h. Membrane was probed with anti-p53 and anti-dUTPase, anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls. Histogram bars represents mean &#177; SEM from two independent replicates, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption>
###xml 2760 2760 2725 2725 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn910f6"/>
###xml 1128 2760 1128 2725 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="69">p53-mediated downregulation of dUTPase does not require p21. <bold>(A</bold>) Western blot demonstrating equivalent and physiologically relevant ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p21<sup>&#8211;/&#8211;</sup> cell line. (<bold>B</bold>) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 &#181;g) co-transfected with pCI-Neo:p53<sup>WT</sup> and pCI-Neo:p53<sup>MUT</sup> (0.2 &#181;g) in the p21<sup>&#8211;/&#8211;</sup> cell line. (<bold>C</bold>) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) (0.2 &#181;g) following treatment with 1 &#181;M oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1 in HCT116 p21<sup>&#8211;/&#8211;</sup> cells. All histogram bars represents mean &#177; SEM of three independent promoter experiments, transfections were performed as outlined in &#8216;Experimental Procedures.&#8217; Numbers on histograms indicate fold-change compared to pGL3:FL. (<bold>D</bold>) qPCR analysis of dUTPase and TS mRNA in HCT116 p21<sup>&#8211;/&#8211;</sup> cells following treatment with 1 &#181;M oxaliplatin for 24 h compared to time-matched control set at 100%. (<bold>E</bold>) Western blot in HCT116 p21<sup>&#8211;/&#8211;</sup> cells following treatment with 1 &#181;M oxaliplatin for 48 h. Membrane was probed with anti-p53 and anti-dUTPase, anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls. Histogram bars represents mean &#177; SEM from two independent replicates, *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="gkn910f6"/></fig>
Previous studies have demonstrated that p53-mediated induction of the cell-cycle inhibitor p21 following genotoxic stress resulted in repression of a number of genes (40,41). We therefore used the HCT116 p21-/- cells, possessing p53WT but lacking p21 protein to investigate the possible influence of p53-mediated transactivation of p21 on dUTPase promoter activity and gene expression. Western blot analysis previously confirmed the expression of p53 but lack of expression of p21 in these cells (Figure 3C). Western blot analysis confirmed similar levels of p53 overexpression in these cells as the p53+/+ and p53-/- cells following transfection with the pCI-Neo:p53WT and pCI-Neo:p53MUT (Figure 6A). We utilized the pGL3:FL dUTPase promoter construct and analyzed the effects of wild type and mutant p53 expression on luciferase activity. Co-transfection of the pGL3:FL with pCI-Neo:p53WT resulted in 5-fold reduction in luciferase activity. Interestingly, co-transfection of pGL3:FL with the pCI-Neo:p53MUT resulted in a 3.65-fold induction in luciferase activity similar to results obtained in the p53+/+ cells (Figure 6B). Figure 6.p53-mediated downregulation of dUTPase does not require p21. (A) Western blot demonstrating equivalent and physiologically relevant ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p21-/- cell line. (B) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 microg) co-transfected with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p21-/- cell line. (C) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) (0.2 microg) following treatment with 1 microM oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1 in HCT116 p21-/- cells. All histogram bars represents mean +/- SEM of three independent promoter experiments, transfections were performed as outlined in 'Experimental Procedures.' Numbers on histograms indicate fold-change compared to pGL3:FL. (D) qPCR analysis of dUTPase and TS mRNA in HCT116 p21-/- cells following treatment with 1 microM oxaliplatin for 24 h compared to time-matched control set at 100%. (E) Western blot in HCT116 p21-/- cells following treatment with 1 microM oxaliplatin for 48 h. Membrane was probed with anti-p53 and anti-dUTPase, anti-beta-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls. Histogram bars represents mean +/- SEM from two independent replicates, *P < 0.05, **P < 0.01, ***P < 0.001.
###end p 68
###begin p 69
###xml 61 63 61 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A</bold>
###xml 240 242 240 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 258 261 258 261 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 285 288 281 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 301 302 297 298 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 435 437 427 429 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 453 456 445 448 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 480 483 468 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 496 497 484 485 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 720 723 700 703 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 953 954 931 932 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1006 1009 984 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1118 1119 1092 1093 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1147 1150 1121 1124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1588 1589 1553 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1600 1601 1565 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1613 1614 1578 1579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
p53-mediated downregulation of dUTPase does not require p21. (A) Western blot demonstrating equivalent and physiologically relevant ectopic expression of wild-type p53 and mutant p53 protein following transient transfection with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p21-/- cell line. (B) Fold-change in luciferase activity of dUTPase full length (pGL3:FL) promoter construct (0.2 microg) co-transfected with pCI-Neo:p53WT and pCI-Neo:p53MUT (0.2 microg) in the p21-/- cell line. (C) Fold-change in luciferase activity of dUTPase full-length promoter (pGL3:FL) (0.2 microg) following treatment with 1 microM oxaliplatin and 100 nM mithramycin A compared to pGL3:FL untreated control set at 1 in HCT116 p21-/- cells. All histogram bars represents mean +/- SEM of three independent promoter experiments, transfections were performed as outlined in 'Experimental Procedures.' Numbers on histograms indicate fold-change compared to pGL3:FL. (D) qPCR analysis of dUTPase and TS mRNA in HCT116 p21-/- cells following treatment with 1 microM oxaliplatin for 24 h compared to time-matched control set at 100%. (E) Western blot in HCT116 p21-/- cells following treatment with 1 microM oxaliplatin for 48 h. Membrane was probed with anti-p53 and anti-dUTPase, anti-beta-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with oxaliplatin-treated samples expressed as a percentage of appropriate untreated time-matched controls. Histogram bars represents mean +/- SEM from two independent replicates, *P < 0.05, **P < 0.01, ***P < 0.001.
###end p 69
###begin p 70
###xml 219 222 219 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 292 295 292 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 416 424 416 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 554 556 554 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
###xml 816 819 812 815 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 849 852 845 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 860 863 856 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 880 888 876 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 988 991 984 987 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1087 1090 1079 1082 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1098 1106 1090 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
The ability of DNA-damage-induced p53 to repress the dUTPase promoter in the absence of p21 induction was subsequently analyzed. Following treatment with oxaliplatin, the pGL3:FL promoter was repressed 5-fold in the p21-/- cells which is identical to the observed repression in the HCT116 p53+/+ cells. Mithramycin A was used as a positive control and significantly suppressed the pGL3:FL promoter activity 20-fold (Figure 6C). To further establish a direct mechanism of transcriptional repression of dUTPase in the absence of p21, we utilized the PlexorTM multiplex qPCR and analyzed dUTPase and TS mRNA expression following treatment with oxaliplatin. Treatment with 1 microM oxaliplatin for 24 h resulted in a >2-fold reduction in dUTPase mRNA. A small but significant reduction in TS mRNA was observed in the p21-/- cells consistent with the p53+/+ and p53-/- isogenic cells (Figure 6D). Finally, western blotting confirmed that dUTPase protein expression was downregulated in the p21-/- cells following treatment with 1 microM oxaliplatin at 48 h in a manner consistent with the p53+/+ cells (Figure 6E). These data suggest that the oxaliplatin-induced transcriptional repression of dUTPase is independent of the p53-transactivation target p21 and is more likely a direct transcriptional effect of p53 expression.
###end p 70
###begin title 71
Oxaliplatin-induced repression of the dUTPase promoter requires functional Sp1 sites
###end title 71
###begin p 72
###xml 995 998 991 994 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
Reports suggested that the transcriptional repression of p53 can be exerted either through direct binding of p53 protein or via its sequestering of transcription factors required for promoter activity. To investigate the downregulation of dUTPase in response to oxaliplatin treatment, we utilized ChIP in conjunction with qPCR to analyze changes at the dUTPase promoter. This approach allows for quantitative analysis of the target region of the dUTPase promoter by normalizing DNA immunoprecipated (IP) with the antibody of interest directly to control IgG IP DNA with a subsequent calibration against 'input' DNA. This method accounts for non-specific antibody binding and variations in input DNA concentration and allows for sensitive quantification of alterations at the dUTPase promoter in response to drug treatment. Following treatment with 1 microM oxaliplatin and 100 nM mithramycin A for 12 h, we performed ChIP analysis using antibodies against Sp1, E2F-1, Ac-H3 and p53 in HCT116 p53+/+ cells and compared to untreated controls. We successfully detected basal Ac-H3, E2F-1, Sp1 and p53 enrichment at the dUTPase promoter compared to the IgG control in the region containing the Sp1 and E2F consensus sequences (-39 to -260).
###end p 72
###begin p 73
###xml 422 430 422 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 757 765 757 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 889 892 889 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1138 1146 1138 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1377 1385 1377 1385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1615 1617 1611 1613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 2061 2070 2053 2062 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7.</label>
###xml 2198 2199 2190 2191 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2245 2252 2237 2244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2379 2382 2367 2370 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2625 2626 2611 2612 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2865 2866 2841 2842 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2899 2902 2875 2878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 3123 3124 3085 3086 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 3214 3217 3176 3179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 3514 3515 3473 3474 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 3626 3629 3585 3588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 4201 4202 4137 4138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 4213 4214 4149 4150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 4226 4227 4162 4163 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2070 4257 2062 4193 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="74">Oxaliplatin-induced, p53-mediated repression of dUTPase is mediated through Sp1 sites and results in the accumulation of dUTP. (<bold>A</bold>) Chromatin immunoprecipitation demonstrating <italic>in vivo</italic> alterations in Sp1 and p53 enrichment at the dUTPase promoter following 12 h treatment with 1 &#181;M oxaliplatin in HCT116 p53<sup>+/+</sup> cells. qPCR was performed using primers encompassing the E2F and Sp1 sites in the dUTPase promoter from &#8722;39 to &#8722;260 as indicated. Histogram bars represent mean &#177; SE from two independent immunoprecipitations analyzed in triplicate by qPCR. (<bold>B</bold>) Fold-change in luciferase activity of dUTPase promoter constructs (0.2 &#181;g) treated with 1 &#181;M oxaliplatin compared to untreated control set at 1, histogram bars represents mean &#177; SE from three independent promoter experiments. (<bold>C</bold>) Growth inhibition of HCT116 p53<sup>+/+</sup> cells treated with 5-FU (0.5 &#181;M), FUdR (0.1 &#181;M) and oxaliplatin (0.5 &#181;M) and combinations. Histogram represents the mean &#177; SEM fraction of cells affected (FA) following three independent 72 h incubations. (<bold>D</bold>) Western blot following treatment with 5-FU, FUdR and combinations for 48 h in HCT116 p53<sup>+/+</sup> cells, membrane was probed with anti-dUTPase, anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of appropriate untreated time-matched control set at 100%. (<bold>E</bold>) dUTP accumulation assay measuring intracellular dUTP as a percentage of the total dUTP/TTP pool in HCT116 p53<sup>+/+</sup> cells following treatment with the TS-inhibitors 5-FU (0.5 &#181;M), FUdR (0.1 &#181;M) for 24 h and oxaliplatin (0.5 &#181;M) for 24 and 48 h. Combinations were performed by incubating with oxaliplatin (0.5 &#181;M) for 24 h, media was removed, cells were washed and re-incubated in media containing the appropriate TS-inhibitor or the microtubule-stabilizing agent paclitaxel (20 nM) as a non-TS-directed control. Histogram bars represents mean &#177; SEM from two independent experiments performed in duplicate. &#8224; indicates that dUTP was not detected in cell extracts. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p>
###xml 2070 4257 2062 4193 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="74">Oxaliplatin-induced, p53-mediated repression of dUTPase is mediated through Sp1 sites and results in the accumulation of dUTP. (<bold>A</bold>) Chromatin immunoprecipitation demonstrating <italic>in vivo</italic> alterations in Sp1 and p53 enrichment at the dUTPase promoter following 12 h treatment with 1 &#181;M oxaliplatin in HCT116 p53<sup>+/+</sup> cells. qPCR was performed using primers encompassing the E2F and Sp1 sites in the dUTPase promoter from &#8722;39 to &#8722;260 as indicated. Histogram bars represent mean &#177; SE from two independent immunoprecipitations analyzed in triplicate by qPCR. (<bold>B</bold>) Fold-change in luciferase activity of dUTPase promoter constructs (0.2 &#181;g) treated with 1 &#181;M oxaliplatin compared to untreated control set at 1, histogram bars represents mean &#177; SE from three independent promoter experiments. (<bold>C</bold>) Growth inhibition of HCT116 p53<sup>+/+</sup> cells treated with 5-FU (0.5 &#181;M), FUdR (0.1 &#181;M) and oxaliplatin (0.5 &#181;M) and combinations. Histogram represents the mean &#177; SEM fraction of cells affected (FA) following three independent 72 h incubations. (<bold>D</bold>) Western blot following treatment with 5-FU, FUdR and combinations for 48 h in HCT116 p53<sup>+/+</sup> cells, membrane was probed with anti-dUTPase, anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of appropriate untreated time-matched control set at 100%. (<bold>E</bold>) dUTP accumulation assay measuring intracellular dUTP as a percentage of the total dUTP/TTP pool in HCT116 p53<sup>+/+</sup> cells following treatment with the TS-inhibitors 5-FU (0.5 &#181;M), FUdR (0.1 &#181;M) for 24 h and oxaliplatin (0.5 &#181;M) for 24 and 48 h. Combinations were performed by incubating with oxaliplatin (0.5 &#181;M) for 24 h, media was removed, cells were washed and re-incubated in media containing the appropriate TS-inhibitor or the microtubule-stabilizing agent paclitaxel (20 nM) as a non-TS-directed control. Histogram bars represents mean &#177; SEM from two independent experiments performed in duplicate. &#8224; indicates that dUTP was not detected in cell extracts. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption>
###xml 4257 4257 4193 4193 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn910f7"/>
###xml 2061 4257 2053 4193 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F7" position="float"><label>Figure 7.</label><caption><p textid="74">Oxaliplatin-induced, p53-mediated repression of dUTPase is mediated through Sp1 sites and results in the accumulation of dUTP. (<bold>A</bold>) Chromatin immunoprecipitation demonstrating <italic>in vivo</italic> alterations in Sp1 and p53 enrichment at the dUTPase promoter following 12 h treatment with 1 &#181;M oxaliplatin in HCT116 p53<sup>+/+</sup> cells. qPCR was performed using primers encompassing the E2F and Sp1 sites in the dUTPase promoter from &#8722;39 to &#8722;260 as indicated. Histogram bars represent mean &#177; SE from two independent immunoprecipitations analyzed in triplicate by qPCR. (<bold>B</bold>) Fold-change in luciferase activity of dUTPase promoter constructs (0.2 &#181;g) treated with 1 &#181;M oxaliplatin compared to untreated control set at 1, histogram bars represents mean &#177; SE from three independent promoter experiments. (<bold>C</bold>) Growth inhibition of HCT116 p53<sup>+/+</sup> cells treated with 5-FU (0.5 &#181;M), FUdR (0.1 &#181;M) and oxaliplatin (0.5 &#181;M) and combinations. Histogram represents the mean &#177; SEM fraction of cells affected (FA) following three independent 72 h incubations. (<bold>D</bold>) Western blot following treatment with 5-FU, FUdR and combinations for 48 h in HCT116 p53<sup>+/+</sup> cells, membrane was probed with anti-dUTPase, anti-&#946;-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of appropriate untreated time-matched control set at 100%. (<bold>E</bold>) dUTP accumulation assay measuring intracellular dUTP as a percentage of the total dUTP/TTP pool in HCT116 p53<sup>+/+</sup> cells following treatment with the TS-inhibitors 5-FU (0.5 &#181;M), FUdR (0.1 &#181;M) for 24 h and oxaliplatin (0.5 &#181;M) for 24 and 48 h. Combinations were performed by incubating with oxaliplatin (0.5 &#181;M) for 24 h, media was removed, cells were washed and re-incubated in media containing the appropriate TS-inhibitor or the microtubule-stabilizing agent paclitaxel (20 nM) as a non-TS-directed control. Histogram bars represents mean &#177; SEM from two independent experiments performed in duplicate. &#8224; indicates that dUTP was not detected in cell extracts. *<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001; NS, not significant.</p></caption><graphic xlink:href="gkn910f7"/></fig>
Following treatment with 100 nM mithramycin A, Ac-H3 enrichment was reduced 2-fold consistent with decreased gene transcription whereas Sp1 enrichment was decreased 2.4-fold consistent with mithramycin A displacing Sp1 at the GC-rich dUTPase promoter. E2F-1 enrichment was not modulated in response to mithramycin A. Significantly, enrichment of the tumor suppressor p53 remained unchanged in mithramycin A treated cells (Figure 7A). Treatment with oxaliplatin resulted in a significant 2-fold reduction in Sp1 accompanied by a modest decrease in E2F-1 and Ac-H3 enrichment at the dUTPase promoter. Significantly, enrichment of p53 was increased 2.3-fold at the dUTPase promoter following treatment with oxaliplatin, when compared to the untreated control (Figure 7A). In an attempt to identify the p53-responsive element in the dUTPase promoter, we subsequently transfected the HCT116 p53+/+ cells with the dUTPase Sp1 and E2F site-mutant promoter constructs and compared the repression by oxaliplatin to the full-length construct. Importantly, these site mutant constructs retained significant transcriptional activity in HCT116 cells (Figure 1D). The full-length promoter was repressed 5-fold by oxaliplatin. The E2F site-mutant was repressed by oxaliplatin 3-fold. However, mutation of the triple Sp1 sites completely abrogated the oxaliplatin-induced promoter repression (Figure 7B) suggesting that p53 is acting on the region of the promoter containing the Sp1 sites. To confirm that the mutations within the pGL3:Sp1Delta construct efficiently impair Sp1 binding, we performed EMSA analysis. Using a dUTPase 32P-labelled probe encompassing the triple Sp1-binding sites (-64 to -91), we demonstrate binding of recombinant Sp1 (rhSp1) to both this sequence and a control Sp1 consensus oligo. However, a mutant probe corresponding to the Sp1 site mutations within the pGL3:Sp1Delta construct failed to compete for binding with rhSp1 (). This data supports the hypothesis that repression of the dUTPase promoter by oxaliplatin requires functional Sp1 sites. Figure 7.Oxaliplatin-induced, p53-mediated repression of dUTPase is mediated through Sp1 sites and results in the accumulation of dUTP. (A) Chromatin immunoprecipitation demonstrating in vivo alterations in Sp1 and p53 enrichment at the dUTPase promoter following 12 h treatment with 1 microM oxaliplatin in HCT116 p53+/+ cells. qPCR was performed using primers encompassing the E2F and Sp1 sites in the dUTPase promoter from -39 to -260 as indicated. Histogram bars represent mean +/- SE from two independent immunoprecipitations analyzed in triplicate by qPCR. (B) Fold-change in luciferase activity of dUTPase promoter constructs (0.2 microg) treated with 1 microM oxaliplatin compared to untreated control set at 1, histogram bars represents mean +/- SE from three independent promoter experiments. (C) Growth inhibition of HCT116 p53+/+ cells treated with 5-FU (0.5 microM), FUdR (0.1 microM) and oxaliplatin (0.5 microM) and combinations. Histogram represents the mean +/- SEM fraction of cells affected (FA) following three independent 72 h incubations. (D) Western blot following treatment with 5-FU, FUdR and combinations for 48 h in HCT116 p53+/+ cells, membrane was probed with anti-dUTPase, anti-beta-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of appropriate untreated time-matched control set at 100%. (E) dUTP accumulation assay measuring intracellular dUTP as a percentage of the total dUTP/TTP pool in HCT116 p53+/+ cells following treatment with the TS-inhibitors 5-FU (0.5 microM), FUdR (0.1 microM) for 24 h and oxaliplatin (0.5 microM) for 24 and 48 h. Combinations were performed by incubating with oxaliplatin (0.5 microM) for 24 h, media was removed, cells were washed and re-incubated in media containing the appropriate TS-inhibitor or the microtubule-stabilizing agent paclitaxel (20 nM) as a non-TS-directed control. Histogram bars represents mean +/- SEM from two independent experiments performed in duplicate. dagger indicates that dUTP was not detected in cell extracts. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant.
###end p 73
###begin p 74
###xml 128 129 128 129 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 175 182 175 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 309 312 305 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 555 556 549 550 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 795 796 779 780 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 829 832 813 816 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1053 1054 1023 1024 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1144 1147 1114 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 1444 1445 1411 1412 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1556 1559 1523 1526 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 2131 2132 2075 2076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2143 2144 2087 2088 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2156 2157 2100 2101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Oxaliplatin-induced, p53-mediated repression of dUTPase is mediated through Sp1 sites and results in the accumulation of dUTP. (A) Chromatin immunoprecipitation demonstrating in vivo alterations in Sp1 and p53 enrichment at the dUTPase promoter following 12 h treatment with 1 microM oxaliplatin in HCT116 p53+/+ cells. qPCR was performed using primers encompassing the E2F and Sp1 sites in the dUTPase promoter from -39 to -260 as indicated. Histogram bars represent mean +/- SE from two independent immunoprecipitations analyzed in triplicate by qPCR. (B) Fold-change in luciferase activity of dUTPase promoter constructs (0.2 microg) treated with 1 microM oxaliplatin compared to untreated control set at 1, histogram bars represents mean +/- SE from three independent promoter experiments. (C) Growth inhibition of HCT116 p53+/+ cells treated with 5-FU (0.5 microM), FUdR (0.1 microM) and oxaliplatin (0.5 microM) and combinations. Histogram represents the mean +/- SEM fraction of cells affected (FA) following three independent 72 h incubations. (D) Western blot following treatment with 5-FU, FUdR and combinations for 48 h in HCT116 p53+/+ cells, membrane was probed with anti-dUTPase, anti-beta-actin was used to control for loading; histogram represents corresponding cell lysates subjected to dUTPase catalytic activity assay with treated samples expressed as a percentage of appropriate untreated time-matched control set at 100%. (E) dUTP accumulation assay measuring intracellular dUTP as a percentage of the total dUTP/TTP pool in HCT116 p53+/+ cells following treatment with the TS-inhibitors 5-FU (0.5 microM), FUdR (0.1 microM) for 24 h and oxaliplatin (0.5 microM) for 24 and 48 h. Combinations were performed by incubating with oxaliplatin (0.5 microM) for 24 h, media was removed, cells were washed and re-incubated in media containing the appropriate TS-inhibitor or the microtubule-stabilizing agent paclitaxel (20 nM) as a non-TS-directed control. Histogram bars represents mean +/- SEM from two independent experiments performed in duplicate. dagger indicates that dUTP was not detected in cell extracts. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not significant.
###end p 74
###begin title 75
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
Oxaliplatin induces accumulation of dUTP alone and in combination with TS-inhibitors in HCT116 p53+/+cells
###end title 75
###begin p 76
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 297 305 293 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 824 827 820 823 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 924 932 920 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1006 1014 1002 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1758 1766 1742 1750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 2797 2805 2765 2773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
Oxaliplatin is clinically approved for the treatment of colon cancer and is primarily used in combination with 5-FU or capecitabine where these drugs demonstrate synergistic anti-tumor activity (37). Given the novel observation that a clinically relevant concentration of oxaliplatin (0.5 microM, Figure 4A) can acutely downregulate dUTPase protein in a p53-dependent manner in a colon cancer model, we sought to test the possible clinical implications of this by measuring the accumulation of dUTP, a downstream cytotoxic event induced by chemotherapeutics that inhibit TS. We utilized 5-FU whose effects include TS-inhibition, and incorporation of fluorinated nucleotides into DNA and RNA and the more specific TS-inhibitor FUdR which induces only DNA-directed effects. First, we confirmed that the treatment of HCT116 p53+/+ cells with oxaliplatin and either 5-FU or FUdR for 72 h resulted in enhanced growth inhibition (Figure 7C) and resulted in downregulation of dUTPase protein and enzyme activity (Figure 7D). To verify that the effects on dUTP accumulation with drug combinations were a specific effect of TS-inhibition, we included the microtubule-stabilizing agent paclitaxel as a non-TS-directed control agent. Intracellular dUTP was measured using a polymerase-based nucleotide pool assay which detects both TTP and dUTP from cell extracts, with subsequent incubation with recombinant dUTPase indicating the contribution of dUTP as a percentage of the total dUTP/TTP detected. No dUTP was detected in untreated control cells or following treatment with the sub-cytotoxic concentrations of 0.1 microM FUdR and 0.5 microM 5-FU at 24 h. Following treatment with 0.5 microM oxaliplatin alone for 24 h, there was no detectable dUTP in cell extracts (Figure 7E). However, treatment with 0.5 microM oxaliplatin alone for 48 h resulted in the significant accumulation of dUTP. Specifically, within the total dUTP/TTP pool, 15.4% was dUTP, correlating with the acute reduction in dUTPase expression and activity previously noted. When cells were treated with oxaliplatin for 24 h followed by 0.1 microM FUdR or 0.5 microM 5-FU for a further 24 h, dUTP accumulation was significantly increased to 28% and 25% respectively of the total dUTP/TTP pool. To confirm that this effect was a direct result of downregulation of dUTPase followed by subsequent TS inhibition, we used the control combination of 0.5 microM oxaliplatin for 24 h followed by the non-TS-directed microtubule stabilizing drug paclitaxel (20 nM) for 24 h. This resulted in the detection of <3% of dUTP in the total dUTP/TTP, and would suggest that the increase in dUTP accumulation observed with 5-FU/FUdR and oxaliplatin combinations was a direct result of the TS metabolic blockade in the absence of an active dUTPase enzyme (Figure 7E). These data suggest that suppression of dUTPase by oxaliplatin may enhance the fluoropyrimidine-induced accumulation of dUTP and may contribute to the synergistic interaction between these agents.
###end p 76
###begin title 77
DISCUSSION
###end title 77
###begin p 78
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 419 422 419 422 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 557 565 557 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 729 737 729 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 936 946 936 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Drosophila</italic>
###xml 958 966 958 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1117 1125 1117 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1240 1247 1240 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1269 1277 1269 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1323 1325 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 1326 1328 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 1329 1331 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1344 1349 1344 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44 B45 B46 B47">44&#8211;47</xref>
###xml 1702 1704 1702 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1705 1707 1705 1707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 1708 1710 1708 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 936 946 <span type="species:ncbi:7227">Drosophila</span>
Expression of dUTPase in malignant cells demonstrates significant variation, both in total expression and subcellular localization which may account for differences in clinical response to the TS-inhibiting class of chemotherapeutics (10). Therefore, elucidating the molecular basis for variable dUTPase expression is of interest from both a basic science and clinical perspective. Using promoter analysis in HCT116 p53+/+ colon cancer cells, the region containing the E2F and triple Sp1 site was found to be sufficient for driving DUT-N promoter activity (Figure 1A and B). Site-directed mutagenesis of the E2F and Sp1 sites clearly demonstrated that both transcription factors positively contribute to basal promoter activity (Figure 1C and D). We also report that the dUTPase promoter is highly responsive to Sp1 overexpression in HCT116 colon cells and silent in the absence of Sp1 and responsive to Sp1 expression in Sp1-deficient Drosophila SL2 cells (Figure 2A). Furthermore, knockdown of Sp1 resulted in the downregulation of dUTPase protein expression and significantly attenuated dUTPase promoter activity (Figure 2C). Finally we confirmed the presence of both Sp1 and E2F-1 transcription factors at the proximal dUTPase promoter in vivo using ChIP and qPCR (Figure 2D). Interestingly, dysregulation of both Sp1 (33,42,43) and E2F-1 (44-47) are widely observed following neoplastic transformation and are reported to contribute to a variety of tumor processes including progression, drug resistance, angiogenesis and metastasis. It is therefore likely that dysregulation of E2F-1 and Sp1 expression may contribute to the wide variation in dUTPase expression levels observed in tumor tissues (10,16,17).
###end p 78
###begin p 79
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 356 363 356 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 414 416 414 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 477 485 477 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 551 554 551 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 616 618 616 618 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 650 653 650 653 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 694 696 694 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 776 779 776 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 849 852 849 852 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 879 882 879 882 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 960 963 960 963 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 1197 1200 1197 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MUT</sup>
###xml 1450 1452 1450 1452 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WT</sup>
###xml 1454 1456 1454 1456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
Initial reports identified dUTPase mRNA as modulated by both mutant and wild-type p53 (22,24). However, the precise mechanism by which wild-type p53 exerts its repressive effects on dUTPase has not been described. To our knowledge, this report provides the first evidence demonstrating that dUTPase is directly modulated at the transcriptional level by an in vivo promoter association with p53. Introduction of p53WT resulted in significant repression of the dUTPase promoter (Figure 3C and E). Interestingly, the level of repression in the HCT116 p53-/- cells was significantly greater following introduction of p53WT when compared to the HCT116 p53+/+ cells, suggesting that expression of p53WT already exerts a regulatory influence on the dUTPase promoter in the HCT116 p53+/+ cells. This is further supported by the observation that when the p53MUT is introduced into the p53+/+ cells, the promoter activity is induced to a much greater extent than the p53-/- cells. This phenomenon may be exacerbated due to the artificial nature of the luciferase system, but would indicate the disruption of an unknown mediator involved in dUTPase promoter regulation by the dysregulated interactions of p53MUT. This observation has previously been noted in the TSP50 gene which is negatively regulated by p53, where the authors reported that introduction of mutant p53 significantly increased the TSP50 promoter activity in the three cell lines containing p53WT (48). These data would further suggest that tumoral p53 status and mutation may be important regulators of dUTPase expression and thus may influence chemotherapeutic response.
###end p 79
###begin p 80
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 501 503 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 506 514 506 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 652 660 652 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4 F5">Figure 4</xref>
###xml 698 701 698 701 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8211;/&#8211;</sup>
###xml 916 924 916 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4 F5">Figure 4</xref>
###xml 1473 1475 1473 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 1818 1820 1818 1820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 2066 2068 2066 2068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 2530 2532 2530 2532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 2754 2756 2754 2756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 2757 2759 2757 2759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 3348 3356 3348 3356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 3512 3520 3512 3520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 3198 3201 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
It is important to consider that ectopic p53 expression is unlikely to accurately simulate p53 activation in response to DNA damage which involves complex post-translation modifications. We therefore utilized chemotherapeutic agents used in the treatment of colorectal cancer which are known to activate p53 including the DNA-damaging agent oxaliplatin and the TS-inhibitors 5-FU and FUdR. Both 5-FU and FUdR resulted in a modest downregulation of dUTPase protein consistent with previous reports (21,49) (Figure 4A). However, for the first time, we identified oxaliplatin as a potent downregulator of dUTPase at the promoter, mRNA and protein levels (Figure 4B and 5A). Treatment of the HCT116 p53-/- cells with the same clinically relevant doses of oxaliplatin failed to modulate the dUTPase promoter or downregulate mRNA and protein expression, indicating a direct role for p53 or a p53-target in the repression (Figure 4B, 5A and B). Moreover, our findings indicate that this acute downregulation preceded complete cell cycle arrest with rapid repression of the dUTPase promoter and downregulation of the mRNA within 24 h. Although both 5-FU and FUdR result in similar levels of p53 induction, the cytotoxicity induced by these agents is of a significantly different nature than oxaliplatin. Specifically, 5-FU and FUdR are reported to initiate rapid S-phase arrest which is associated with thymidylate depletion as a result of TS-inhibition and is independent of p53 (50). The induction of p53 in response to 5-FU is reported to be a later event, possibly due to aberrant detection of uracil and fluoronucleotides in synthesized DNA. Oxaliplatin binds with high affinity to GC-rich DNA forming bulky platinum adducts which block DNA replication, activate p53 and stimulate the nucleotide excision repair pathway (51). Importantly, oxaliplatin treatment in HCT116 cells was previously reported to initiate a p53-dependent cell cycle arrest, indicating an immediate role for p53 in mediating the cellular response to oxaliplatin in the HCT116 colon cancer model (52). A recent report directly compared the p53 response in colon cancer cells treated with 5-FU compared to the direct DNA-damaging agent doxorubicin. The authors noted that 5-FU treatment did not accumulate p53 or result in p53 phosphorylation until 24 h post-treatment. However, doxorubicin treatment resulted in rapid p53 induction through protein stabilization and noted that p53 protein was both rapidly phosphorylated and acetylated within 4 h of treatment (53). Furthermore, p53 signaling is a complex pathway involving multiple post-translational modifications which are specific to its subsequent functions which vary markedly from cell-cycle arrest and DNA repair to apoptosis (54,55). Considering that oxaliplatin is also a direct DNA-damaging agent, it is possible that the mechanism of resultant p53 activation and associated post-translational modifications are markedly different than those observed following treatment with 5-FU and FUdR and this may account for the difference in the ability of these agents to repress dUTPase gene expression. We also note that ectopic dUTPase protein expression from an exogenous CMV-driven promoter was unaffected by oxaliplatin, discounting protein stability or atypical turnover and supporting a direct transcriptional effect (Figure 5D). Simultaneous analysis of TS, another classical S-phase gene revealed only a moderate downregulation following oxaliplatin treatment independent of p53 (Figure 5C), supporting the idea that the presence of a p53 responsive element is a key difference between the regulation of TS and dUTPase.
###end p 80
###begin p 81
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 351 359 351 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 560 568 560 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 790 793 790 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 1179 1181 1179 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 1276 1279 1276 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1326 1328 1326 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 2107 2115 2107 2115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 2213 2220 2213 2220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2236 2238 2236 2238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 2239 2241 2239 2241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 2275 2277 2275 2277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 2458 2460 2458 2460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 2564 2566 2564 2566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
Previous reports suggested that p53-mediated transactivation of p21 was sufficient and necessary to exert the negative gene regulation of p53 (40). By using a p21 HCT116 null isogenic cell line, we demonstrate that p21 is not required for the transcriptional repression of dUTPase in response to oxaliplatin, further suggesting a direct role for p53 (Figure 6). We subsequently confirmed the presence and enrichment of p53 at the dUTPase proximal promoter following treatment with oxaliplatin. Importantly, this was accompanied by reductions in Sp1 and Ac-H3 (Figure 7A). Although the exact mechanism by which p53 represses the dUTPase promoter is not clear, these observations suggest that p53 interacts with the dUTPase promoter transcriptional machinery in the absence of a p53-specific cis element to suppress gene expression. In support of our observations, additional reports demonstrated p53-mediated transcriptional repression of the protective antioxidant enzyme manganese superoxide dismutase and the anti-apoptotic molecule MCL-1 in the absence of a p53 consensus site and demonstrated this to be mediated through disruption of normal transcription factor binding (56,57). Furthermore, the DNA repair enzyme AP-endonuclease is repressed by p53, in the absence of a cis element through interfering with Sp1 binding (58). This model is supported by our findings which demonstrated increased p53 and reduced Sp1 at the dUTPase promoter following oxaliplatin treatment. Interestingly, treatment with mithramycin A, which directly reduced Sp1 enrichment, did not show enrichment for p53, suggesting that displacing Sp1 or additional Sp-family members at the dUTPase promoter or inhibiting additional Sp1-driven gene expression can abrogate the promoter enrichment of p53. In support of this, our observation that the triple Sp1 site-mutant construct, which importantly still retained 50% transcriptional activity of the full-length construct, was not repressed by oxaliplatin and would further indicate that p53 is exerting its repressive effects through the region of the promoter known to bind Sp1 (Figure 7B). Previous studies have demonstrated that p53 can directly associate with transcription factors in vivo including Sp1 (57,59) and with histone deacetylase 1 (60) and repress transcription from specific promoters. Importantly, it has also been demonstrated that mutant p53 lacks the capacity to interact with HDAC1 and repress transcription (60), representing another possible mechanism for the p53-mutant induction of dUTPase previously reported (24) and our observations in this report showing p53-mutant induction of the dUTPase promoter. Furthermore, the inability of mutant forms of p53 to repress gene transcription may contribute to associated chemoresistance by abrogating apoptosis induced through repression of protective genes.
###end p 81
###begin p 82
###xml 191 192 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 196 198 196 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B62">62</xref>
###xml 435 437 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B63">63</xref>
###xml 674 677 674 677 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 956 964 956 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1184 1192 1184 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F8">Figure 8</xref>
###xml 1195 1204 1195 1204 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 8.</label>
###xml 1204 1923 1204 1923 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="83">Working model of p53-mediated repression of dUTPase transcription and subsequent enhancement of 5-FU-mediated downstream effects. Schematic diagram illustrating the downstream effects of p53-mediated transcriptional repression of dUTPase following treatment with a clinically relevant dose of oxaliplatin. The model proposes that p53 induction following DNA damage may inhibit dUTPase transcription via interaction with or inhibition of transcription machinery. Subsequent treatment with 5-FU results in TS-inhibition and, in the absence of an active dUTPase enzyme, promotes the accumulation of dUTP within cells, promoting increased DNA damage through uracil misincorporation in the presence of a TS-inhibiting agent.</p>
###xml 1204 1923 1204 1923 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="83">Working model of p53-mediated repression of dUTPase transcription and subsequent enhancement of 5-FU-mediated downstream effects. Schematic diagram illustrating the downstream effects of p53-mediated transcriptional repression of dUTPase following treatment with a clinically relevant dose of oxaliplatin. The model proposes that p53 induction following DNA damage may inhibit dUTPase transcription via interaction with or inhibition of transcription machinery. Subsequent treatment with 5-FU results in TS-inhibition and, in the absence of an active dUTPase enzyme, promotes the accumulation of dUTP within cells, promoting increased DNA damage through uracil misincorporation in the presence of a TS-inhibiting agent.</p></caption>
###xml 1923 1923 1923 1923 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn910f8"/>
###xml 1195 1923 1195 1923 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F8" position="float"><label>Figure 8.</label><caption><p textid="83">Working model of p53-mediated repression of dUTPase transcription and subsequent enhancement of 5-FU-mediated downstream effects. Schematic diagram illustrating the downstream effects of p53-mediated transcriptional repression of dUTPase following treatment with a clinically relevant dose of oxaliplatin. The model proposes that p53 induction following DNA damage may inhibit dUTPase transcription via interaction with or inhibition of transcription machinery. Subsequent treatment with 5-FU results in TS-inhibition and, in the absence of an active dUTPase enzyme, promotes the accumulation of dUTP within cells, promoting increased DNA damage through uracil misincorporation in the presence of a TS-inhibiting agent.</p></caption><graphic xlink:href="gkn910f8"/></fig>
As a single agent, oxaliplatin has limited clinical activity in colorectal cancer and is primarily used in combination with 5-FU or capecitabine resulting in synergistic anti-tumor activity (3,37,61). Attempts to define the molecular basis for this synergistic interaction have demonstrated that oxaliplatin induces modest suppression of both TS mRNA and activity of the 5-FU catabolic enzyme dihydropyrimidine dehydrogenase (DPD) (62,63). In the present study, we confirmed that oxaliplatin induced a modest downregulation of TS mRNA independent of p53 and p21. In addition, we provide the first evidence of a p53-dependent acute downregulation of dUTPase in the HCT116 p53+/+ colon cell line following treatment with a clinically relevant dose of oxaliplatin. When oxaliplatin was combined with a TS-inhibitor, there was a significant increase in the accumulation of dUTP consistent with downregulation of dUTPase and increased effects of TS-inhibition (Figure 7E). Targeted use of oxaliplatin in tumors with elevated levels of dUTPase and wild-type p53 may represent a novel strategy for improving the therapeutic efficacy of TS-directed agents and warrants further investigation (Figure 8). Figure 8.Working model of p53-mediated repression of dUTPase transcription and subsequent enhancement of 5-FU-mediated downstream effects. Schematic diagram illustrating the downstream effects of p53-mediated transcriptional repression of dUTPase following treatment with a clinically relevant dose of oxaliplatin. The model proposes that p53 induction following DNA damage may inhibit dUTPase transcription via interaction with or inhibition of transcription machinery. Subsequent treatment with 5-FU results in TS-inhibition and, in the absence of an active dUTPase enzyme, promotes the accumulation of dUTP within cells, promoting increased DNA damage through uracil misincorporation in the presence of a TS-inhibiting agent.
###end p 82
###begin p 83
Working model of p53-mediated repression of dUTPase transcription and subsequent enhancement of 5-FU-mediated downstream effects. Schematic diagram illustrating the downstream effects of p53-mediated transcriptional repression of dUTPase following treatment with a clinically relevant dose of oxaliplatin. The model proposes that p53 induction following DNA damage may inhibit dUTPase transcription via interaction with or inhibition of transcription machinery. Subsequent treatment with 5-FU results in TS-inhibition and, in the absence of an active dUTPase enzyme, promotes the accumulation of dUTP within cells, promoting increased DNA damage through uracil misincorporation in the presence of a TS-inhibiting agent.
###end p 83
###begin p 84
Additional genes with critical roles in cytoprotection and survival including anti-apoptotic, oxidative stress elimination and DNA repair genes have previously been demonstrated to be repressed by p53, promoting the hypothesis that the pro-apoptotic function of p53 is mediated in part through transcriptional repression of cytoprotective genes. It is therefore plausible that the p53-mediated repression of dUTPase may enhance DNA damage and represent one component in the commitment to irreversible cell death and contribute to the tumor suppressing functions governed by p53.
###end p 84
###begin p 85
###xml 87 92 <span type="species:ncbi:9606">human</span>
In conclusion, p53 plays a critical role in the transformation and progression of many human malignancies, thus, the effect of p53 on uracil-DNA metabolism may increase our understanding of the complex regulatory pathways governed by p53 and may assist in providing more targeted chemotherapy. Our results have identified and characterized a novel mechanism of p53-dependent transcriptional regulation of an evolutionary conserved and essential enzyme involved in regulating intracellular uracil pools and maintaining genomic stability.
###end p 85
###begin title 86
SUPPLEMENTARY DATA
###end title 86
###begin p 87
 are available at NAR Online.
###end p 87
###begin title 88
FUNDING
###end title 88
###begin p 89
###xml 4 32 4 32 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institute of Health</grant-sponsor>
###xml 38 52 38 52 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5R21CA104796-3</grant-num>
###xml 103 131 103 131 <grant-sponsor xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">National Institute of Health</grant-sponsor>
###xml 137 151 137 151 <grant-num xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5R21CA104796-3</grant-num>
The National Institute of Health R21 (5R21CA104796-3, 5P30CA14089-33). Funding for open access charge: National Institute of Health R21 (5R21CA104796-3).
###end p 89
###begin p 90
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 90
###begin title 91
Supplementary Material
###end title 91
###begin title 92
[Supplementary Data]
###end title 92
###begin title 93
ACKNOWLEDGEMENTS
###end title 93
###begin p 94
We would like to thank Dr Guntram Suske from the Institut Fur Molekularbiologie und Tumorforschung (Marburg, Germany) for the kind gift of the Sp1 expression vectors and Dr Bert Vogelstein from the John Hopkins University (Baltimore, MD) for the kind gift of the HCT116 isogenic cell lines. We would also like to thank Dr Michael R. Stallcup and Peter J. Baumeister for critically reviewing this manuscript.
###end p 94
###begin title 95
REFERENCES
###end title 95
###begin article-title 96
###xml 61 77 <span type="species:ncbi:562">Escherichia coli</span>
Lethality of a dut (deoxyuridine triphosphatase) mutation in Escherichia coli
###end article-title 96
###begin article-title 97
###xml 47 71 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
dUTP pyrophosphatase is an essential enzyme in Saccharomyces cerevisiae
###end article-title 97
###begin article-title 98
5-fluorouracil: mechanisms of action and clinical strategies
###end article-title 98
###begin article-title 99
Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole
###end article-title 99
###begin article-title 100
The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition
###end article-title 100
###begin article-title 101
###xml 84 108 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
dUTPase and uracil-DNA glycosylase are central modulators of antifolate toxicity in Saccharomyces cerevisiae
###end article-title 101
###begin article-title 102
###xml 14 19 <span type="species:ncbi:9606">human</span>
Modulation of human dUTPase using small interfering RNA
###end article-title 102
###begin article-title 103
###xml 77 82 <span type="species:ncbi:9606">human</span>
###xml 112 128 <span type="species:ncbi:562">Escherichia coli</span>
Induction of resistance to fluorodeoxyuridine cytotoxicity and DNA damage in human tumor cells by expression of Escherichia coli deoxyuridinetriphosphatase
###end article-title 103
###begin article-title 104
Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition
###end article-title 104
###begin article-title 105
dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer
###end article-title 105
###begin article-title 106
Novel opportunities for thymidylate metabolism as a therapeutic target
###end article-title 106
###begin article-title 107
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human dUTP pyrophosphatase: uracil recognition by a beta hairpin and active sites formed by three separate subunits
###end article-title 107
###begin article-title 108
###xml 21 26 <span type="species:ncbi:9606">human</span>
Kinetic mechanism of human dUTPase, an essential nucleotide pyrophosphatase enzyme
###end article-title 108
###begin article-title 109
###xml 95 100 <span type="species:ncbi:9606">human</span>
Active site closure facilitates juxtaposition of reactant atoms for initiation of catalysis by human dUTPase
###end article-title 109
###begin article-title 110
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human dUTPase gene encodes both nuclear and mitochondrial isoforms. Differential expression of the isoforms and characterization of a cDNA encoding the mitochondrial species
###end article-title 110
###begin article-title 111
Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331
###end article-title 111
###begin article-title 112
Expression of deoxyuridine triphosphatase (dUTPase) in colorectal tumours
###end article-title 112
###begin article-title 113
E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints
###end article-title 113
###begin article-title 114
###xml 82 87 <span type="species:ncbi:9606">human</span>
A tyrosine kinase inhibitor, beta-hydroxyisovalerylshikonin, induced apoptosis in human lung cancer DMS114 cells through reduction of dUTP nucleotidohydrolase activity
###end article-title 114
###begin article-title 115
Functional proteomics of resveratrol-induced colon cancer cell apoptosis: caspase-6-mediated cleavage of lamin A is a major signaling loop
###end article-title 115
###begin article-title 116
Transcriptional profiling of MCF7 breast cancer cells in response to 5-fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53
###end article-title 116
###begin article-title 117
Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression
###end article-title 117
###begin article-title 118
p53 over-expression and p53 mutations in colon carcinomas: relation to dietary risk factors
###end article-title 118
###begin article-title 119
Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil
###end article-title 119
###begin article-title 120
###xml 43 48 <span type="species:ncbi:9606">human</span>
Identification of sequence determinants of human nuclear dUTPase isoform localization
###end article-title 120
###begin article-title 121
###xml 64 69 <span type="species:ncbi:9606">human</span>
Characterization of distinct nuclear and mitochondrial forms of human deoxyuridine triphosphate nucleotidohydrolase
###end article-title 121
###begin article-title 122
Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers
###end article-title 122
###begin article-title 123
Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay
###end article-title 123
###begin article-title 124
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method
###end article-title 124
###begin article-title 125
A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity
###end article-title 125
###begin article-title 126
Distinct roles for Sp1 and E2F sites in the growth/cell cycle regulation of the DHFR promoter
###end article-title 126
###begin article-title 127
Cell cycle-regulated association of E2F1 and Sp1 is related to their functional interaction
###end article-title 127
###begin article-title 128
Sp transcription factor family and its role in cancer
###end article-title 128
###begin article-title 129
Inhibition of p53-mediated transcriptional responses by mithramycin A
###end article-title 129
###begin article-title 130
Regulation of p53 in response to DNA damage
###end article-title 130
###begin article-title 131
Drug resistance, predictive markers and pharmacogenomics in colorectal cancer
###end article-title 131
###begin article-title 132
###xml 93 101 <span type="species:ncbi:9606">patients</span>
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial
###end article-title 132
###begin article-title 133
Proteolytic degradation of the nuclear isoform of uracil-DNA glycosylase occurs during the S phase of the cell cycle
###end article-title 133
###begin article-title 134
Fluorodeoxyuridine Modulates Cellular Expression of the DNA Base Excision Repair Enzyme Uracil-DNA Glycosylase
###end article-title 134
###begin article-title 135
p21/CDKN1A mediates negative regulation of transcription by p53
###end article-title 135
###begin article-title 136
p53-dependent down-regulation of telomerase is mediated by p21waf1
###end article-title 136
###begin article-title 137
###xml 78 83 <span type="species:ncbi:9606">human</span>
Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer
###end article-title 137
###begin article-title 138
###xml 157 165 <span type="species:ncbi:9606">patients</span>
Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer
###end article-title 138
###begin article-title 139
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase
###end article-title 139
###begin article-title 140
Role of retinoblastoma protein and E2F-1 transcription factor in the acquisition of 5-fluorouracil resistance by colon cancer cells
###end article-title 140
###begin article-title 141
Role of E2F-1 in chemosensitivity
###end article-title 141
###begin article-title 142
E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis
###end article-title 142
###begin article-title 143
TSP50 encodes a testis-specific protease and is negatively regulated by p53
###end article-title 143
###begin article-title 144
The action of Pdcd4 may be cell type specific: evidence that reduction of dUTPase levels might contribute to its tumor suppressor activity in Bon-1 cells
###end article-title 144
###begin article-title 145
Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies
###end article-title 145
###begin article-title 146
Oxaliplatin: mechanism of action and antineoplastic activity
###end article-title 146
###begin article-title 147
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan
###end article-title 147
###begin article-title 148
###xml 62 67 <span type="species:ncbi:9606">human</span>
Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells
###end article-title 148
###begin article-title 149
Participation of p53 protein in the cellular response to DNA damage
###end article-title 149
###begin article-title 150
DNA damage activates p53 through a phosphorylation-acetylation cascade
###end article-title 150
###begin article-title 151
###xml 32 37 <span type="species:ncbi:9606">human</span>
p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter
###end article-title 151
###begin article-title 152
###xml 60 65 <span type="species:ncbi:9606">human</span>
Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression
###end article-title 152
###begin article-title 153
###xml 18 23 <span type="species:ncbi:9606">human</span>
Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage
###end article-title 153
###begin article-title 154
Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C
###end article-title 154
###begin article-title 155
Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a
###end article-title 155
###begin article-title 156
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
###end article-title 156
###begin article-title 157
Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells
###end article-title 157
###begin article-title 158
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences
###end article-title 158

